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ABSTRACT 
Background: The homeopathic preparation, Traumeel S, has been used as a valuable 
alternative to conventional non-steroidal anti-inflammatory drugs (NSAIDS) for over 30 years. 
This antihomotoxic, anti-phlogistic drug has been widely used by sportsmen and women in the 
treatment of lesions and inflammatory processes which result from exercise-induced skeletal 
muscle microtrauma. Although numerous randomised, double-blind placebo-controlled trials 
have confirmed the efficacy of Traumeel S as an anti-inflammatory agent, there are few in vivo 
studies which have specifically investigated the mechanism by which Traumeel S is effective in 
reducing inflammatory response to exercise-induced muscle cell damage. 
Aim: To establish whether the administration of Traumeel S during the five days before 
participation and three days following participation, significantly attenuates the systemic markers 
of the inflammatory response, following a 90-minute downhill running trial. 
Method: Twenty-four healthy athletes (14 men and 10 women), aged 20-50 years, were 
recruited for this study. Following baseline laboratory testing and familiarisation with the 
treadmill as well as a field test, subjects were matched according to gender, BMI, training age, 
training status, peak performance and foot strike patterns and randomised into Traumeel (TRS) 
and Control (PLAC) groups in a placebo-controlled, double-blind design. One Traumeel S or 
Placebo tablet was ingested three times per day for five days prior to and three days following a 
90-minute exercise trial on a downhill (-6% gradient) at 75% V02 max- Blood samples were 
collected prior to the 90-minute trial (PRE), immediately after the trial (IPE) and 24 hours (24 
PE), 48 hours (48 PE) and 72 hours (72 PE) following the trial. Each subject was also 
requested to complete a training record prior to the trial and keep a record of the daily symptoms 
of delayed onset muscle soreness (DOMS) both at rest (general pain) and during walking (daily 
living). Full blood counts (FBC), serum creatine kinase (CK), lactate dehydrogenase (LDH) and 
Cortisol concentrations were measured using standard haematological laboratory procedures 
and serum C-Reactive Protein (CRP) was determined by immunoturbidimetric assay. Sandwich 
ELISA's were used to determine myeloperoxidase (MPO) and plasma interleukin-6 (IL-6) 
concentrations. All results obtained were adjusted for changes in plasma volume as calculated 
from the red blood cell indices. 
Results: Mean ± SD characteristics of the gender-matched subjects in the experimental (TRS) 
and placebo-control (PLAC) groups did not differ significantly in terms of BMI, age, % body fat, 
FVC, FEVi, training age and status, foot strike pattern or peak running performance, maximal 
Heart Rate, VE, V02peak> RER, RPE during the maximal exercise test (p > 0.05). This indicated 
that the randomised pairs were well matched. 
The 90-minute downhill running protocol resulted in significant elevations in total circulating 
white blood cell count (WBC), neutrophil, CK, LDH, Cortisol, CPR, MPO and IL-6 concentrations 
(p < 0.001). When comparing the TRS and PLAC groups, mean ± SD total and differential WBC 
count, neutrophil count, CK, LDH, Cortisol, CPR, MPO and IL-6 concentrations did not differ 
(p > 0.05) over the 5 time points. At 24 PE, MPO concentrations were significantly higher in the 
TRS group than in the PLAC group (p = 0.03). The lower mean ± SD post-trial DOMS scores 
reported by the TRS group were not significantly different from those reported by the PLAC 
group (p > 0.05). 
Conclusion: Although the findings of this study did not identify differences in circulating CK, 
LDH, Cortisol, CPR and IL-6 concentrations between the TRS and PLAC groups, the elevated 
MPO concentration at 24 PE did provide preliminary novel evidence of enhanced activation of 
neutrophil oxidative burst activity following exercise-induced muscle damage which is 
hypothesized to accelerate the recovery process. 
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1.1. INTRODUCTION TO THE PROBLEM 
Traumeel S is a homeopathic formulation available in oral tablet form, as a subcutaneous 
injection, as oral drops, oral liquids in vials and as a topical ointment. It is an anti-homotoxic, 
anti-phlogistic drug which has been used as a valuable alternative to conventional non-steroidal 
anti-inflammatory (NSAIDS) drugs for over 30 years, due to its reported anti-inflammatory, 
analgesic, anti-oedematous and anti-exudate properties. It has been widely used by sportsmen 
and sportswomen in the treatment of lesions and inflammatory processes which result from 
exercise-induced skeletal muscle microtrauma. Although numerous randomised, double-blind, 
placebo-controlled trials have confirmed its efficacy as an anti-inflammatory agent, little is known 
of its scientific mechanisms of action. 
In vitro studies have shown that Traumeel S is non-cytotoxic to granulocytes, lymphocytes, 
platelets and endothelial cells and that the functions of these cells are not impaired by Traumeel 
S (Porozov et al., 2004; Conforti ef a/., 1997) and to modulate the production of reactive oxygen 
species (ROS) during oxidative burst activity in the neutrophils (Conforti et al., 1997). In studies 
on whole blood cultures, Traumeel S has been shown to elevate levels of Transforming Growth 
Factor Beta (TGF-p), which is an anti-inflammatory cytokine synthesised by T-Helper Type 3 
(TH3) lymphocytes (Heine and Adnra, 2002). 
In the most recent in vitro work, Porozov et al. (2004) examined the effects of Traumeel S on the 
ability of resting and activated phytohemagglutinin (PHA) and phorbol myristate acetate (PMA) 
activated human T cells, monocytes, and gut epithelial cells, to secrete the pro-inflammatory 
mediators, tumour necrosis factor-a (TNF-a), interleukin-ip (IL-1P), and interleukin-8 (IL-8) over 
a period of 24 to 72 hours. While IL-ip activation was reduced by up to 70% in both resting and 
active cells, TNF-a activation was reduced by up to 65% in resting cells and 54% in active cells 
and IL-8 activation was reduced by 50% in both resting and active cells (p < 0.01 for all cells). 
Traumeel S did not appear to affect T cell and monocyte proliferation and maximal inhibition was 
maintained with dilution of the Traumeel S stock material. In this particular study it was 
concluded that Traumeel S does not inhibit immune cell functions by exerting a toxic effect 
(Porozov et al., 2004). 
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An in vivo study was conducted on 50 individuals (26 on Traumeel S and 24 on placebo) at the 
Sports Research Institute of Pretoria University which required the participants to run for 45 
minutes on a treadmill at a downhill gradient of -10% (Jordaan, 2006). The full blood counts, 
rate of perceived exertion (RPE) and blood pressure recordings, as well as serum Cortisol, 
lactate and creatine kinase (CK) concentrations were measured, but only RPE, heart rate (HR) 
and Cortisol concentration showed significant differences between the two groups with the 
experimental group being significantly higher than the control group in all three measurements. 
As matching of the subjects, demographical details and training status of the subjects were not 
reported and few markers of exercise-induced muscle damage were assessed, further work is 
required and conclusions cannot be drawn from the available findings. 
This study was therefore conducted to validate and extend upon the above-mentioned findings 
and to investigate whether the results of previous in vitro work could be replicated in an in vivo 
setting. 
1.2. AIMS AND OBJECTIVES OF THE STUDY 
• To confirm that 90 minutes of downhill treadmill running results in an elevation, within the 
circulation of leukocyte, neutrophil and monocyte numbers, selected muscle enzymes 
(creatine kinase, lactate dehydrogenase), acute phase proteins (C-Reactive Protein), Cortisol, 
interleukin-6 and myeloperoxidase in the circulation. 
• To establish whether administration of Traumeel S (during the five days before participation 
and three days following participation) significantly attenuates these systemic markers of 
inflammatory response, following a 90-minute downhill running trial. 
1.3. HYPOTHESES 
In keeping with consistent previous findings regarding inflammatory response to downhill 
running and eccentric exercise (Peake et al., 2005a; Aoi et al., 2004; Braun and Dutto, 2003; 
Malm et al., 1999; Byrnes et al., 1985), the following one-directional alternate hypothesis was 
set: 
Downhill running will result in an elevation of neutrophil count and serum creatine 
kinase (CK), lactate dehydrogenase (LDH), C-Reactive Protein (CRP), 
myeloperoxidase (MPO), interleukin-6 (IL-6) and Cortisol concentrations in the 
circulation. 
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As the results of previous studies investigating the effect of Traumeel S on inflammatory 
response in an in vitro setting, are limited and inconclusive, the following non-directional, null 
hypothesis was set for this aspect of the study: 
Traumeel S administration will not have an effect on systemic markers of an 
inflammatory response to 90 minutes of downhill running. 
1.4. SCOPE AND LIMITATIONS 
This double blind, placebo-controlled study was restricted to two sets of 12 (n = 24) experienced, 
well-trained athletes, who were matched for gender, body mass index (BMI), training status and 
training age as well as at least two of the following: foot strike, maximal oxygen consumption 
(V02max)> 1609m running time and/or best performance over longer endurance running events 
within six months prior to the study trials. 
After maximal exercise capacity was assessed in the Human Performance Laboratory and 
running biomechanics and 1609m running time were assessed during a field-side evaluation on 
an athletics track, each subject completed a -6% downhill 90-minute treadmill run at a workload 
which elicited 75% of V02max on a level treadmill. Five days prior to the trial run, each subject 
ingested either a Traumeel S preparation or a placebo provided by Heel (Pty) Ltd. Red blood 
cell (RBC) indices and differential leukocyte counts as well as circulating concentrations of 
muscle enzymes, Cortisol, CRP, IL-6 and MPO were measured from venous blood samples 
taken pre-, immediately post (IPE) 24 hours post (24 PE), 48 hours post (48 PE) and 72 hours 
post (72 PE) each exercise-trial, to establish whether a significant difference existed between 
TRS and placebo-control (PLAC) trials over this time-period. Subjective perceptions of post-
exercise delayed onset muscle soreness (DOMS) were also monitored during the 72 hours 
following each exercise trial. 
Due to the undisputed evidence which is now available regarding the repeated bout effect viz. 
the adaptive response to acute repeated exposure to similar bouts of eccentric exercise 
(Nosaka et al., 2005; McHugh, 2003; Nosaka and Newton, 2002; Stupka et a/., 2001), it was not 
possible to conduct a crossover study. In order to eliminate a training effect as a potential 
confounder in the study, this double-blind, placebo-controlled study was therefore designed 
using pairs of runners who were matched according to gender, mass, training history, training 
age as well as athletic performance and/or foot strike in order to ensure sufficient external 
validity. As it was necessary to design this study within the framework of financial constraints as 
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well as difficulty in obtaining full compliance from the subjects, the sample size was restricted to 
12 gender-matched couples (n = 24). 
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CHAPTER TWO 
REVIEW OF THE RELATED LITERATURE 
2.1. INTRODUCTION 
Acute bouts of prolonged exposure to exercise have been shown to cause damage to muscle at 
the cellular level (Nieman, 1997). The degree of this damage is determined by the intensity and 
nature of the exercise causing disturbances to the contractile units inside the muscle (Stupka et 
al., 2000). This microscopic damage has also been associated with the release of inflammatory 
mediators (Maclntyre et al., 1995; Pyne 1994), which trigger an inflammatory response in an 
attempt to repair the damage and eliminate the toxic substances (Roitt er al., 2001). 
Exercise-induced muscle inflammation has also been reported to result in the synthesis of large 
quantities of prostaglandins of the E series (PGE-2), which have been reported to sensitise Type 
II and IV pain nociceptors and activate afferents and are thought to be responsible for delayed 
onset muscle soreness (DOMS) (Aoi et al., 2004; Smith, 1991; Byrnes et al., 1985). This can 
negatively affect the intensity of subsequent training sessions and prevent adherence to 
exercise programmes. Muscle inflammation and DOMS has also been shown to adversely 
affect the running economy 48 hours following a downhill run (Braun and Dutto, 2003). 
2.2. EXERCISE-INDUCED MUSCLE DAMAGE AND ACUTE INFLAMMATORY RESPONSE 
2.2.1. Tissue Disruption 
Exercise of high intensity and particularly exercise of an eccentric nature, has been shown to 
result in myofibrillar disruption and cell membrane damage (Friden and Lieber, 1992; Smith, 
1991). Disturbances in the excitation-contraction coupling (Frennette et al., 2002) and calcium 
signalling have also been reported to be impaired owing to damage from exercise (Overgaard et 
al., 2002; Armstrong, 1990). 
Damage to the sarcomere is thought to occur due to Z-line disruption (Magaudda et al., 2004). 
This disruption to the myocyte and its cell membrane is thought to be the result of a break down 
of desmin, a protein that connects the adjacent Z-lines (Figure 2.1) to the different myofibrils 
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(Boriek etal., 2001). The breakdown has also been reported to cause subsequent streaming of 
the Z-lines (Grobler etal., 2004; Stupka etal., 2000). 
Figure 2.1: Schematic illustration of muscle structure depicting the Z-line (Lodish et al., 2000) -
Reproduced with permission from Dr. Harvey Lodish 
The degree of Z-line disturbance is an indication of damage to the protein filaments within the 
sarcoplasm. Complex cellular and humoral responses, in conjunction with the connective tissue 
disruption and cell membrane damage, result in the release of various intracellular components 
into the blood stream (Smith, 2003; Lambert and Denis, 1994). Muscle proteins which have 
been found to leak from the compromised cell membrane, include creatine kinase (Totsuka etal., 
2002; Clarkson et al., 1992), myoglobin (Croisier et al., 1996), fatty acid binding protein 
(Sorichter et al., 1998), lactate dehydrogenase (Overgaard et al., 2002; Nosaka and Clarkson, 
1996) and skeletal muscle troponin I (Sorichter et al., 1997). The changes in the muscle 
structure and subsequent increase of muscle proteins and enzymes in the bloodstream have 
been shown to result in a loss of muscle strength and range of motion (Peake et al., 2005a; 
Nosaka etal., 2005). 
2.2.2. Markers of Muscle Cell Damage 
Serum creatine kinase (CK) and lactate dehydrogenase (LDH) have been the most commonly 
reported direct indicators of exercise-induced muscle cell membrane damage (Braun and Dutto, 
2003; Overgaard et al., 2002; Hortobagyi et al., 1998). The literature is consistent in reporting 
peak LDH concentrations in serum immediately post-exercise, while a peak in the CK 
concentration has been shown to occur between 12-24 hours post-exercise (Semple etal., 2007; 
Simpson etal., 2006; Armstrong, 1990). 
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Conflicting evidence, however, exists as to which mode of exercise produces the greatest 
changes in CK activity (Sorichter et al., 1997; Clarkson et al., 1992). Sorichter et al. (1997) 
reported that changes in CK activity were relative to exercise intensity, duration and volume and 
that the subjects familiarity with eccentric exercise would also affect changes in serum CK, 
while Clarkson et al. (1992) reported that changes in CK activity after isometric exercise were 
similar to those that occur in downhill running but that the increase in CK activity in the blood 
tended to be substantially lower after downhill running (approximately 300 lU/f), when 
compared with high force eccentric exercise of the forearm flexors (approximately 2,500 \\J/l). 
Clarkson et al. (1992) concluded that changes in CK activity differ relative to muscle mass 
recruitment during exercise. This was confirmed by Peters et al. (2001a, 2005) who reported 
CK concentrations as high as 3050 IU/€ following participation in the 1997 downhill Comrades 
Marathon and 20-fold increases in CK following the same 90km downhill event in 1999. 
Interestingly, the corresponding increases in serum LDH were only 2-fold and peaked 
immediately post exercise as opposed to the serum CK concentrations which peaked at 24 
hours post-exercise. 
As large intra- and inter-individual differences have been reported to occur in both LDH and CK 
(Peters et al., 2005), investigators have sought other more reliable indicators. In 1997 Sorichter 
et al. conducted a study which revealed that skeletal muscle troponin I (sTnl) is an initial specific 
marker of exercise-induced muscle injury. In 1998 Sorichter et al. subsequently also found 
plasma fatty acid binding protein (FABP) to be a better indicator of muscle injury than CK. This 
finding was based on the rapid increase and decrease that was recorded in FABP following 
eccentric exercise and indicated that FABP is more practical in detecting early muscle damage. 
Damage which occurs to the muscle cell membrane, also indirectly activates mast cells in the 
connective tissue to start degranulation and release their contents. These include heparin, 
histamine, serotonin and bradykinin. Vasodilatation, which results in an increased blood supply 
at the injured site, occurs as a result of the histamine release (Ganong, 2005). An increase in 
the permeability of the vascular walls will also occur, allowing easy release of fluids and defence 
cells and subsequent swelling. Increases in the vascular wall permeability will also accelerate 
diapedesis of neutrophils and monocytes through vessel walls and disrupt calcium homeostasis 
(Armstrong et al., 1983). 
An influx of calcium into the cell through the compromised cell membrane has also been shown 
to activate Phospholipase A (Gissel, 2000). As seen in Figure 2.2 below, this activation of 
phospholipase results in the release of membrane glycerophospholipids, from the activated 
mast cell (Ganong, 2005). 
CELL DAMAGE 
Activation of Phospholipase A 
MEMBRANE GLYCEROPHOSPHOLIPIDS RELEASE 
ARACHIDONIC ACID 
Cyclo-oxygenase Lipoxygenases CYP mono-oxygenases 
PROSTAGLANDINS LEUKOTRIENES EPOXYEICOSATRIENOIC 
ACID 
Figure 2.2: Principal biologically active substances produced from arachidonic acid in response to exercise-
induced muscle cell damage & activation of mast cells (Ganong, 2005) 
Arachidonic acid from the membrane glycerophospholipids is converted into prostaglandins by 
the enzymatic action of cyclo-oxygenase (COX) and into leukotrines by the enzymatic activity of 
lipoxygenase (Ganong, 2005; Van Brandt, 2002). 
2.2.3. Satellite Cells 
Disruption of the myocyte and its membrane also activate the macrophages which reside in the 
muscle tissue and these are thought to contribute to the activation and proliferation of satellite 
cells within the damaged area (Grounds, 1991). These cells are known to play an important role 
in the repair and remodelling of the damaged muscle cells through the process of terminal 
differentiation, which lasts up to 10 days. They are myogenic precursor cells which later 
differentiate into myoblasts and fuse to form myotubes. The myotubes are reported to form 
myofibrils, which are then re-innervated to form mature muscle fibres (Hawke and Garry, 2001). 
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2.2.4. Pro-Inflammatory Cytokine Release 
Activation of the macrophages residing in the damaged tissue will also result in the production 
and release of pro-inflammatory cytokines, specifically TNF-a, interleukin-1 (IL-1) and 
interleukin-6 (IL-6), which is currently better known for its inhibition of pro-inflammatory action 
via its activation of the adrenal cortex to release Cortisol (Nieman, 1997). These cytokines have 
also been shown to increase cell permeability and together with the chemotactic cytokine, IL-8, 
and macrophage chemoattractant and activating factor (MACF) facilitate the migration of 
neutrophils and monocytes towards the site of tissue damage and inflammation. Through this 
influx of leukocytes and the clearance of antigens, healing can begin to occur (Roitt et al., 2001). 
2.2.5. Adhesion Molecule Expression on Leukocytes 
Within a few hours after tissue injury, there is a dramatic increase in the number of circulating 
polymorphonuclear leukocytes (PMNs), primarily neutrophils (Smith et al., 1998). These 
leukocytes then adhere to the venular wall at the site of inflammation due to the increased 
expression of adhesion molecules which arise from the activation of the endothelium lining the 
capillary venules, primarily by histamine, IL-1 and TNF-a. The extended period of vasodilation 
and increased cell wall permeability induced by histamine and heparin promotes diapedesis of 
the neutrophils, monocytes that occur with inflammation, a decrease in the activation of 
monocytes, and an increase in the expression of cell adhesion molecules on the monocytes 
(Pederson and Toft, 2000; Malm era/., 1999; Nieman, 1997). 
This allows interaction to occur between the leukocyte and endothelial cell. This interaction may 
be broken down into three stages: rolling of the PMNs, activation of the PMNs and finally 
adhesion of the PMNs to the endothelial cell (Walzog & Gaehtgens, 2000; Van Eeden et al., 
1999; Casadevall et al., 1999). Different adhesion molecules are responsible for these different 
stages and these have been divided into three basic categories: selectins, integrins and 
immunoglobins (Walzog and Gaehtgens, 2000; Van Eeden era/., 1999; Casadevall et al., 1999). 
The role of selectins is in the capturing of leukocytes and the rolling of these leukocytes onto the 
endothelial cells and platelets. This is achieved by binding to carbohydrate ligands. Integrins, 
on the other hand, bind components of the immunoglobulin group of adhesion molecules and 
hence ensure the holding of leukocytes onto the endothelial cells. These integrins include the 
LFA-1 (CD 11a), Mac-1 (CD 11b) and p150,95 (CD 11c) which are expressed on monocytes 
and neutrophils. The third group of adhesion molecules, the immunoglobulins, as mentioned 
above, serve as ligands for the integrins. The most important of these immunoglobulins are the 
intracellular adhesion molecules (ICAMs), which once bound to the integrins play a key role in 
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ensuring recruitment of PMNs and the adhesion thereof to the site of inflammation (Casadevall 
etal., 1999). 
The binding of leukocytes to endothelial cells is dependent on the binding of (32 integrins 
(including CD 11a, b and c) to the adhesion molecules ICAM-1 or ICAM-2 on the endothelium. 
Less adhesion of leukocytes to endothelium will occur if the expression of adhesion molecules is 
low, or if the adhesion molecules have not been activated. Exercise with resultant increases in 
body temperature, induces the activation of adhesion molecules facilitating the adhesion of 
leukocytes to the endothelium and their movement to the site of inflammation. 
In 1994 Gabriel and Kinderman showed that during intensive exercise, the cells that are 
preferentially mobilised from the marginal blood pool, expressed high levels of the (32 integrin 
LFA-1 (CD11a) than cells that were not mobilised. 
Studies which have examined the effect of exercise on the role and functioning of adhesion 
molecules have found the expression of adhesion molecules to be increased following exercise 
(Malm et al., 1999). Studies have also shown that PMNs, which were released from the 
marginated pool as a result of extensive exercise, expressed low levels of L-selectin and high 
levels of CD11b (Van Eeden et al., 1999). Further research findings suggested that the cell-
surface expression of CD11a molecules is associated with granulocytosis following exercise 
(Kurokawa et al., 1995) and that a significant increase of leukocyte CD11b expression changes, 
negatively influence the ability of leukocytes to adhere to and actively transmigrate the 
endothelium to reach the tissues (Nielsen and Lyberg, 2004). The findings of a study conducted 
by Mills et al. (2006) indicated that immune cells that demarginate in response to exercise, have 
a reduced ability to adhere in individuals who are physically fit. Peake et al. (2004), however, 
showed that neutrophil activation remains unchanged after downhill running in well-trained 
runners, despite increases in plasma markers of muscle damage. 
2.2.6. Neutrophil Activation 
Neutrophils are involved in a number of inflammatory conditions and respond differently when 
exercise is performed at different intensities (Pederson and Hoffman-Goetz, 2000; Suzuki et al., 
1999). There is consensus in the literature that neutrophil function is enhanced in response to 
moderate, sub-maximal, prolonged exercise, resulting in an increase in their chemotaxic activity 
and phagocytic and oxidative burst function (Peters, 1997a). 
On arrival at the site of tissue damage, phagocytes extend their pseudopodia around the foreign 
particles, engulfing them and forming phagosomes which fuse with the neutrophil phagosome 
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granules and release digestive enzymes, including elastase. The membrane vesicles generate 
highly toxic and bacteriocidal reactive oxygen species (ROS) including superoxide radicals 
(02~), hydroxyl radicals (OH) and hypochlorus acid (HOC?). 
The generation of 0 2 ~ is catalysed by activated nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase with the further production of hydrogen peroxide (H202) and ultimately HOC?. 
HOC? is cytotoxic and assists the neutrophils in removing foreign substances introduced into the 
cell following tissue damage. Its production from H202 is catalysed by myeloperoxidase (MPO) 
(Figure 2.3). 
MPO is a peroxidase enzyme which is expressed in neutrophils during oxidative burst activity. 
Bury and Pirnay (1995) reported significant elevations of MPO concentrations in plasma 
following two hours of prolonged exercise at 75% V02 max which peaked at 722 ± 50 ng/m? 
immediately post exercise. They also found that intensity of exercise was an important 
parameter in explaining the magnitude of MPO increase (p < 0.05) and that despite significant 
increases in both the neutrophil count and MPO concentrations (p < 0.001) following exercise, 
MPO concentration and neutrophil number were not significantly correlated (p < 0.05). This 
inferred that neutrophil degranulation is independent of neutrophil mobilisation. However, 
Suzuki et al. produced contradictory evidence in their 1999 study, which showed that the 
increase in the MPO enzyme activity in plasma was proportional to the increase in the number 
of neutrophils after prolonged exercise. 
Camus et al. (1992) compared plasma elastase and myeloperoxidase concentrations following 
uphill walking and downhill running. While both bouts of exercise were accompanied by similar 
increases of 33% above resting values in neutrophil concentration, uphill walking did not result 
in significant elevation in MPO or elastase concentration, but downhill running was followed by a 
97% increase in MPO and a 70% increase in elastase above resting concentrations. These 
findings clearly demonstrate the importance of the eccentric component of muscle contractions 
in neutrophil activation during exercise. 
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Figure 2.3: Membrane-associated oxidative metabolic response to exercise in neutrophils (Modified from 
Peters, 1997a) 
2.2.7. Post Exercise Neutrophilia and Monocytosis 
During prolonged exercise, the absolute number of circulating leukocytes increases significantly 
towards a maximal value. It has been proposed that delayed release of Cortisol during and after 
exercise is responsible for the continued exercise-induced increase in neutrophil count (Peters, 
1997b). Pizza et al. (1995) reported a larger and more persistent elevation of total leukocyte 
and neutrophil number after a 60-minute downhill (-10% gradient) compared with level running. 
These remained significantly higher up to 12 hours after downhill running, suggesting a 
sustained recruitment into the circulation. The magnitude of recruitment of monocytes into the 
circulation during prolonged exercise is however, closely related to exercise intensity and 
duration (Nieman, 1997). Monocytes have been shown to localise to and infiltrate skeletal 
muscle damaged during exercise. It has been suggested that recruitment of these cells into the 
circulation during exercise, followed by their rapid removal after exercise, may reflect the homing 
of these cells to damaged tissue (MacKinnon, 1999). 
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2.2.8. Activation of Hypothalamic-Pituitarv-Adrenal Axis 
Inflammation may also be influenced at a higher level through the hormonal control by the 
hypothalamic-pituitary-adrenal axis when the tissue damage is of a large or more severe nature 
(Kushner, 1982). IL-6, which is produced by the activated macrophages, activates the pituitary 
release of adenocorticotropic hormone (ATCH), which then stimulates the adrenal cortex to 
release two cortical hormones, desoxicortisone and glucocorticoids (Figure 2.4). 
Glucocorticoids promote carbohydrate and protein catabolism, but also play a role in reducing 
swelling and restraining inflammation (Kushner, 1982) 
The rise in serum Cortisol concentration following prolonged eccentric exercise is well 
documented (Peters, 2001a, 2001b). Post exercise Cortisol concentrations have been shown to 
rise by no more than 50% following 60 minutes of downhill treadmill running (gradient -13.5%) at 
75% V02 max (Smith ef a/., 2007), but ± 200% increases to values of 1179 ± 93,2 nmol/t have 
been reported following a 90km downhill ultramarathon run (Peters, 2001b). The exercise-
induced rise in systemic Cortisol concentration is a sequel to stimulation of the adrenal cortex by 
IL-6 and increased concentrations of circulating Cortisol have been reported to act on the bone 
marrow, causing a further release of neutrophils into the blood stream (Steensberg et al., 2003; 
Pederson and Hoefman-Goetz, 2000, Suzuki et al., 1999). Due to the anti-inflammatory 
properties of Cortisol, the inflammation has been theorised to be restrained once Cortisol 
concentrations reach a critical level and the body is given the opportunity to repair the tissue 
(Van Brandt, 2002). Whether greater inhibition of the natural inflammatory response by 
administration of exogenous steroids is advisable, is therefore currently a matter of debate 
(Ritacca era/., 2002). 
2.3. ACUTE PHASE RESPONSE 
A further systemic response to exercise-induced skeletal muscle damage and subsequent 
inflammation is an acute phase response (APR), similar to that which occurs with infections, 
surgery and trauma (Fallon, 2001). While muscle damage results in elevated levels of CK, 
myoglobin, LDH and plasma FABP (Braun and Dutto, 2003; Overgaard et al., 2002; Hortobagyi 
et al., 1998), release of IL-6 from activated macrophages in the tissues and subsequent Cortisol 
from the adrenal cortex stimulates hepatic production of acute phase proteins. These reactants 
include serum amyloid A inducer (SAA), CRP, fibrinogen, haptoglobulin, ceruloplasmin, 
transferrin, and a 2-macroglobulin (Pannen and Robotham, 1995; Weight et al., 1991) and form 
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Figure 2.4: The role of interleukin-6 in the Acute Phase Response 
Fallon (2001) described the hepatic production of acute phase proteins following a track race of 
six days in duration. Of the 11 acute phase reactants measured, six responded as if an acute 
phase response was present. These included serum iron, ferritin, percent transferrin saturation, 
CRP and haptoglobin. The other five, transferrin, albumin, a-1 antitrypsin and complement 
components three and four (C3, C4), did not respond accordingly. Albumin, a-fetoprotein and 
transferrin which decrease during an acute phase reaction, have been labelled negative acute 
phase reactants. However, the complement components C3 and C4 usually increase during an 
APR, contradicting what was found in this study (Fallon, 2001). It is also expected that iron 
metabolism will be affected during exercise-induced inflammation as is seen by the increase in 
serum ferritin and decrease in transferrin. 
Conflicting evidence exists as to whether the APR following exercise is analogous to that 
following surgery and trauma (Smith and Roberts, 1991; Weight et al., 1991; Dufaux and Order, 
1989; McCarthy and Dale, 1988; Taylor et al., 1987; Dickson et al., 1982; Liesen et al., 1977). 
In the 1991 study conducted by Weight et al., it was reported that the metabolic sequelae 
following a 42km marathon were similar, but could not be considered analogous, to the APR 
owing to inconsistencies which existed regarding iron metabolism and plasma protein levels. 
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Fallon (2001), also reported that the APR was not identical across a range of medical conditions 
and that there were differences in the cytokine milieu. 
3.2.1. C-Reactive Protein 
A sensitive indicator of the inflammatory response which is most commonly used in exercise 
studies on humans, is CRP. Studies have shown that CRP concentrations increase 
substantially 24 to 48 hours after acute exercise (Semple, 2006; Peters, 2005, 2001a) and that 
this increase is often more pronounced following exercise of greater intensity owing to the 
muscle damage which is incurred (Semple, 2006). The delay in the increase in serum CRP 
concentrations, which usually only peaks after 24 hours, occurs as hepatic release stimulated by 
an increase in circulating IL-6 concentrations, which occurs in response to its release by muscle 
tissue during exercise (Peters, 2004) and activated tissue macrophages following exercise 
(Nieman, 1997). 
One of the primary functions of this exercise-induced increase in CRP is to assist in 
opsonisation and phagocytosis of bacteria, following injury, inflammation or infection, promoting 
the removal and uptake of the necrotised and damaged tissue (Semple, 2006). CRP also 
contributes to the repair process by activating the complement system as it binds to the first 
component of the cascade. This further enhances the process of opsonisation and 
phagocytosis (Dufaux et al., 1994; Pepys, 1981). 
Clyne and Olshaker (1999) have reported that the values of CRP do not differ between males 
and females with^the averages of the general populations being considered normal when less 
than 5 mg/i (Gabay and Kushner, 1999). Furthermore, no diurnal or seasonal variation has 
been observed in blood CRP values (Pepys, 1981) and it has been reported that the levels of 
CRP in humans are not affected by food intake (Semple, 2006). In addition to this, it has been 
shown that regular aerobic exercise does not reduce circulating CRP levels in adults (Kelley and 
Kelley, 2006; Marcell et al., 2005). 
2.4. ECCENTRIC EXERCISE AND THE REPEATED BOUT EFFECT 
In contrast to concentric exercise during which the muscles shorten while contracting, eccentric 
muscle contraction occurs when muscles lengthen while contracting. This eccentric 
concentration results in a greater load being placed on the muscle due to the recruitment of less 
muscle fibres than during a given amount of concentric contraction. Repeated stress is 
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therefore placed on a smaller number of active fibres, which is thought to result in a greater 
degree of damage, as well as possible necrosis, to the fibres (Edman, 1988; Friden et al., 1983, 
1981). For example, it has been shown that the raised levels of IL-6 following eccentric muscle 
activity by far exceed the levels induced by concentric muscle activity (Pederson et al., 2001) 
when variables, such as duration of the exercise and the timing of the blood sample, are 
controlled. 
Stupka et al. (2000) and Clarkson et al. (1992) have attributed the gender differences which 
occur in response to eccentric exercise, to less of an inflammatory response in women than men. 
Researchers have subsequently also consistently reported that women present with lower 
serum CK activity than men (Stupka etal., 2001; Clarkson and Hubal, 2001; Amelink etal., 1990) 
which has been suggested to be related to possible protection from circulating oestrogen 
(Amelink et al., 1990). Interestingly, gender differences in actual exercise-induced structural 
damage to muscle i.e. sarcomere impairment and Z-line streaming, have however, not yet been 
identified. 
In terms of the inflammatory response to eccentric exercise, Malm et al. (1999) showed that 
despite an increase in the number of circulating monocytes, leukocytes and neutrophils, 
monocyte activity decreased post exercise. It was also determined that an increase in the cell 
adhesion expression on monocytes, the specifically adhesion molecules 62L and CD 11b, 
existed following eccentric exercise. The observed phenotypic changes which occurred in this 
study, were attributed to the altered trafficking of cells between the blood and the lymphoid 
tissue, in response to eccentric exercise. 
Recurring bouts of the same endurance exercise, however, cause less symptoms of muscle 
damage than the initial session. In the study conducted by McKune et al. (2006) on 11 
untrained men, where two 60-minute downhill (-13.5% gradient) treadmill trials were conducted 
14 days apart, there was a significant group-time interaction effect for CK. The findings of this 
study reported a significantly lower (p < 0.001) CK activity at six, nine, 12, and 24 hours after 
the second run than after the first run. This is referred to as "repeated bout effect" (McHugh, 
2003) and is also characterized by less DOMS and torque deficit after the second of two 
separate eccentric exercise bouts (Pettitt et al., 2005). 
Three theories which underlie the concept of repeat bout effect have been proposed by McHugh 
et al. (1999). Firstly, the neural theory postulates that there is a change in the motor unit 
recruitment (Golden and Dudley, 1992), which will result in the extent of damage being reduced 
in subsequent sessions of eccentric exercise. A study conducted by Hortobagyi et al. (1998) 
supports this theory in that their results revealed an increase in strength following repeated 
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bouts of exercise. According to the investigators of this study, these results indicated that better 
distribution of workload among fibres occurred, inferring that there was a more efficient 
recruitment of muscle fibres in the successive training sessions. 
Secondly, the connective tissue theory suggests that the muscles become protected as a result 
of the initial damage (McHugh et al., 1999). This protection is thought to be provided by the 
intermediate filaments within the muscle fibre, which consist of proteins, desmin, vimentin and 
synemin (Frieden and Lieber, 1992; Figure 2.1). These filaments play a role in maintaining the 
structural integrity of the sarcomere by preserving the sarcomere stretch and overlap during 
eccentric exercise. The protection of muscles is therefore thought to be due to an increase in 
intramuscular connective tissue following the initial bout of eccentric exercise (Frieden and 
Lieber, 1992). 
Thirdly, the cellular theory suggests that adaptations occur within the muscle cell following the 
initial bout of eccentric exercise. The adaptations include strengthening of the cell membrane, 
removal of the weak fibres and the longitudinal addition of sarcomeres. By strengthening the 
cell membrane, it is proposed that the influx of calcium into the cell is reduced and therefore the 
cell necrosis, which occurs as a result of this calcium influx, is avoided. Furthermore, the 
addition of sarcomeres is thought to reduce the sarcomere strain and therefore maintain the 
myofilament overlap, which prevents cellular disruption (Byrnes, 1985). 
The processes involved in repair and remodelling of skeletal muscle, following exercise-induced 
damage, ultimately allows the muscle to adapt in response to the mechanical and metabolic 
demands placed on it. The extent of this process of repair and adaptation is unknown, but 
evidence exists to suggest that there is a limit to this capacity for remodelling, which ultimately 
can result in the development of a pathological condition which has been described as "Acquired 
Training Intolerance" (Grobler era/., 2004). 
2.5. DELAYED ONSET MUSCLE SORENESS (POMS) 
A distinguishing feature of DOMS is the delayed onset of pain within the muscle, which occurs 
24 to 48 hours following exercise to which the muscles are not accustomed, with the pain being 
more pronounced following exercise of an eccentric nature (Aoi et al., 2004). Stretching, 
contracting and palpating the affected muscle may elicit the pain associated with DOMS. 
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DOMS was originally attributed to a build up of lactate in previously active muscle fibres (Freund 
et al., 1989). However, the observed reduction in blood and muscle lactate concentration occurs 
within 30 minutes of cessation of exercise (Thomas et al., 2004; Apple and Rogers, 1986), while 
DOMS occurs 24 - 48 hours post exercise. 
DOMS is now thought to be the result of microscopic tearing of the muscle fibres in response to 
the load under which they were worked (Peake et al., 2005b). This muscle degradation which 
has been shown to take place following extreme eccentric exercise, results in disruptions of the 
myofibrils and streaming of the Z-lines, as have been identified on electron micrographs 
(Grobler et al., 2004). In addition to this, swelling may also occur in and around the muscle, 
owing to the disruption of the intracellular calcium homeostasis and the release of muscle 
proteins and enzymes into the bloodstream (Armstrong et al., 1983). This swelling is thought to 
increase the pressure on the adjacent structures and will result in greater muscle pain and 
stiffness (Ross, 1999). 
Other reasons for the delayed onset muscle soreness reported following eccentric exercise have 
also been proposed (Yu et al., 2002). As mentioned previously, with disruption to the myocyte, 
serum markers of inflammation increase. Both CK and LDH concentrations have been shown to 
increase (Byrnes et al., 1985; Schwane et al., 1983) as has prostaglandin E2 (PGE-2), which is 
released by blood vessel walls in response to inflammation (Smith, 1991) and is thought to 
sensitise nociceptors and activate Type II and IV pain afferents, decreasing the threshold of the 
pain receptors in the muscle (Tyers and Haywood, 1979). 
Aoi et al. (2004) also postulated that DOMS could result from phagocyte infiltration and resultant 
production of ROS and other anti-oxidants, which attenuate inflammatory changes. 
Researchers have frequently used downhill running to induce DOMS. Akimoto et al. (2002) 
used three different types of exercise in normal, healthy athletes. These included bicycle 
ergometry exercise at 80% V02max for 16 minutes, 42km marathon running and 30 minutes of 
downhill running at an intensity of ventilation threshold. Close et al. (2004) used 30 minutes of 
running in physically active male subjects at 65% V02max on a flat or a -15% downhill gradient. 
A 30-minute protocol at 60% V02 max and a gradient of 18% was used by Thompson et al. (2004) 
in testing healthy male students. Pizza et al. (1995) had runners complete a 60-minute downhill 
run at a -10% gradient at 70% V02max. The protocol used by Pizza et al. (1995) is similar to that 
of the present research in which a 90-minute downhill run at a - 6 % gradient at a speed which 
equated to 75% V02peak> was used. 
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In conclusion, the above-described factors which contribute to the occurrence of DOMS, 
compromise an athlete's maximum exercise capacity and ability to train (Boriek et al., 2001). 
With the adaptation and repair that occurs following training and the repeated bout effect, which 
was discussed earlier, the occurrence and incidence of DOMS does, however, become less 
apparent with recurring bouts of the same type of endurance exercise. 
2.6. TREATMENT MODALITIES 
Modalities which have been used to alleviate pain for soft tissue injuries include a variety of 
treatments, some are scientifically proven, whilst others remain merely a hypothesis. The one 
modality which is universally recognised is the principle of PRICE (prevention, rest, ice, 
compression and elevation) treatment immediately following injury. However, this in itself is 
surrounded in debate with regard to the icing and intermittent reflex vasodilatation, which occurs 
as seen in the Hunting Response (Guyton and Hall, 1996). This introduces the concept of the 
"Gate Control Theory", another contentious issue, whereby the application of cold 'gates' the 
pain impulse to the brain, acting as a counterirritant and breaking the pain cycle (Guyton and 
Hall, 1996). 
Following the application of PRICE, different choices in pain and inflammation management are 
rather subjective with some athletes preferring massage, others receiving acupuncture, 
hyperbaric oxygen therapy, magnetic treatment, and relaxation techniques (White, 1998). 
However, a widely used and recommended form of inflammatory control is through anti-




COX 1 & 2 
IT 
PROSTAGLANDINS 
Phospholipase A2 or 
Phospholipase C 
ARACHIDONIC ACID 
innxvnfinasps CYP mnnn-nwnfinasps 
LEUKOTRIENES EPOXYEICOSATRIENOIC 
ACID 
Figure 2.5: Point of action of steroidal and non-steroidal anti-inflammatory drugs 
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While steroidal anti-inflammatory drugs act via inhibition of phospholipase and the formation of 
arachidonic acid, the NSAIDS act by inhibiting cyclooxygenase (COX) and hence do not 
interfere with the formation of lipoxygenase (Figure 2.5 above). There are two COX enzymes. 
Type 1 is responsible for the production of cytoprotective prostaglandins which function to 
produce the mucous that lines the stomach as well as to assist in platelet aggregation. COX-2 
enzymes are responsible for the production of inflammatory prostaglandins through the 
conversion of arachidonic acid. Their function is primarily recruitment of inflammatory cells 
towards the damaged muscle (Stovitz and Johnson, 2003). Stovitz and Johnson (2003) are of 
the opinion that blocking the prostaglandins which mediate the inflammatory response however, 
causes a delay in the healing process. 
More commonly reported, the disadvantages of the NSAID treatment regimes are the side 
effects, which occur as a result overuse of this class of drugs. These complications include 
gastrointestinal bleeding, renal and cardiovascular disturbances and respiratory symptoms 
(Stovitz and Johnson, 2003). 
More recently, a more selective COX-2 inhibiting drug has been introduced. This drug inhibits 
the COX-2 enzyme whilst still allowing the functioning of the COX-1 enzymes. It thus allows the 
cytoprotective prostaglandins to be produced at the same time as eliminating the inflammatory 
prostaglandins, thereby reducing the side effects and complications which arise during the use 
of this drug (Stovitz and Johnson, 2003). This concept is yet to be fully evaluated and approved. 
2.7. HOMOTOXICOLOGY 
As previously described, one of the mechanisms of action by which NSAIDS work is to block the 
prostaglandins, which mediate the inflammatory response, causing a delay in the healing of the 
injury. Concerns relating to blocking the inflammatory prostaglandins through the use of 
NSAIDS, has led scientists to examine alternative means of inflammatory control. One of the 
alternative means is the natural science of homotoxicology. 
Homotoxicology focuses on the influence that toxic substances have on the human body. It is a 
combination of traditional eastern concepts including homeopathy, in which an illness is treated 
by administering diluted amounts of an infectious or toxic agent, which would normally cause 
illness in a healthy person, with the purpose of activating the production of specific memory p 
cells which are sensitive to the agent (Bellavite et a/., 2005). 
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In contrast to previously described allopathic treatment which primarily involves the use of 
NSAIDS, naturalists believe that inflammation is necessary to eliminate the toxic substances in 
the body and to repair the injured tissues. They argue that by suppressing the COX-2 enzyme, 
the symptoms of inflammation may be reduced, but the actual cause of the inflammatory 
condition will not have been treated and hence, in their opinion, the allopathic treatment of 
inflammation is purely symptomatic, while the bio-therapeutic and homeopathic approach to 
inflammation is causal and aimed at accelerating the recovery process (Van Brandt, 2002). 
The bio-therapeutic approach is centred on the extra cellular matrix and it aims to stimulate and 
regulate the different components of inflammation, which are proposed to ultimately "speed up" 
the process of healing. This type of treatment is thought to result in the eventual disappearance 
of symptoms and the "neutralisation" of the cause via the degradation of those toxins which are 
responsible for the inflammatory response (Kirkman, 2005). 
Two models upon which homotoxicology is based, exist: Selye's model (1952) and the 
Immunological Bystander Reaction as described by Heine and Schmotz (1998). 
Selye's model is based on the premise that because of damage, a change in pH will occur as a 
result of the release of the stimulating and inhibiting cytokines, within the tissue (Van Brandt, 
2002). It views the process of inflammation as a self-regulating one, which will continue until 
the damaged tissue is restored to its original state. It describes the inflammatory response 
occurring in two stages, with the first stage being referred to as the "shock phase" and the 
second stage an "anti-shock phase". 
The shock phase is identified as beginning when an increase in the activity of phagocytic cells 
occurs (Van Brandt, 2002). The shock phase continues as activation of the cellular immune 
system stimulates the release of IL-1 and TNF-a from the macrophages (antigen-presenting 
cells) and hence the pro-inflammatory and allergic responses are triggered (Van Brandt, 2002; 
Weiner, 2001). 
A subsequent anti-shock phase has been described by Weiner (2001). This is characterised by 
an increase in the secretion of TGF-p from the TH3 lymphocytes. This anti-inflammatory 
cytokine regulates inflammatory processes including cellular proliferation, -differentiation, 
-migration and -apoptosis (Weiner, 2001; Heine and Schmotz, 1998). 
The Immunological Bystander Reaction, as described by Heine and Schmotz (1998), explains 
the effect of anti-inflammatory and anti-homotoxic preparations on inflammation. Traumeel S is 
one such preparation. The model focuses on the effect of the introduction of this anti-homotoxic 
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agent with low potentised protein into the cytoplasm of the damaged tissue, which is viewed by 
homotoxicologists as a biophysical filter between the capillary system, the lymph vessels and 
the inflammatory mediators (Van Brandt, 2002). Heine and Adnra (2002) postulate that once 
the anti-homotoxic agent is inside the cytoplasm, it will be engulfed by macrophages to form 
"motives" on the macrophage. According to the model when these "motives" are recognised by 
the surrounding T-lymphocytes, transformation of the "motive" occurs and TH3 cells are derived, 
which will result in the secretion of TGF-(3 and a subsequent decrease in the activity of TH1 and 
TH2 (Van Brandt, 2002). This is how the Immunological Bystander Reaction proposes that anti-
homotoxic agents can regulate inflammation. 
2.8. TRAUMEEL S 
Traumeel S, a homeopathic formulation containing Arnica Montana and other plant extracts, has 
been used as a valuable alternative to conventional NSAIDS for over 30 years. It is a broad-
spectrum agent, which has a regenerative action. It is composed of a combination of 12 
botanical substances and 2 mineral substances. These include Arnica Montana, radix 
(mountain arnica), Calendula Officianlis (calendula), Hamamelis Virginia (with hazel) Millfolium 
(minfoil), Belladonna (deadly nightshade), Aconitum Napelus (monkshood), Chaomilla 
(chamomile), Symphytum Officinale (comfrey), Bellis Perennis (daisy), Echinea Angustifolia 
(narrow-leafed coneflower), Echinacea Purpea (purple corneflower), Hypericum Perforatum (St 
Johns Wort), Heparsulphuris Calcareum (calcium sulfide) and Mercurius Solubis (no common 
name). 
Traumeel S is used in the treatment of primary and secondary inflammations and when 
compared with the conventional non-steroidal anti-inflammatory drugs, has both the effective 
antiphlogistic and analgesic characteristics. Unlike the conventional NSAID however, Traumeel 
S lacks the deleterious effects of gastro-intestinal toxicity (Arora ef a/., 2002). Furthermore, 
Traumeel S does not inhibit platelet aggregation nor does it have any negative interactions with 
other medications. 
Unfortunately, the exact mechanism of action is unknown and not fully understood. In addition 
to the previously described Immunological Bystander Reaction, Conforti er al. (1997) proposed 
the modulation of the release of oxygen radicals by activating neutrophils. This is thought to 
result in an increase in neutrophilic oxidative burst activity and lymphocyte function as well as 
subsequent inhibition of the release of inflammatory mediators, such as IL-1. Traumeel S is 
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therefore thought to accelerate the healing process and attenuate the inflammatory response by 
stimulating both innate and secondary adaptive immune responses to the tissue damage. 
Despite its long-term use and availability, there are few sport-specific scientific studies, which 
support the preparation's anti-inflammatory effects. In 1989 Zell et al. conducted a placebo 
controlled, randomised, double-blind trial which tested the effectiveness of the Traumeel S 
topical ointment on joint mobility and subjective ratings of pain following sports related ankle 
sprains. Significant reductions in subjective ratings of pain (p < 0.003) and improvement in joint 
mobility (p < 0.03) were shown in patients in the Traumeel S group (p = 33) when compared to a 
placebo group (p = 36), 10 days after the injury. These findings were confirmed by Bohmer and 
Ambrus (1992) who investigated the effect of the topical ointment on recovery following sports 
related injuries in 102 subjects and found that Traumeel S patients resumed their sports 
activities after only 12.1 days in comparison to 13.5 days for patients in the placebo group. 
Wright-Carpenter et al. (2004) more recently followed this work up also showing a significant 
decrease in recovery time following muscle strains in sportsmen and using magnetic resonance 
imaging (MR!) analysis to support the observed acceleration of the lesion recovery time. 
Besides the ointment studies (Bohmer and Ambrus, 1992; Zell, 1989) other studies which have 
been conducted, have used the intra-articular injection (Bimesser et al., 2004; Thiel, 1987) and 
the mouth rinse (Oberbaum et al., 2001) as experimental treatment, but none used the tablet 
form of the preparation. Positive findings that supported the use of Traumeel S as a well-
tolerated alternative anti-inflammatory to NSAIDS were reported in these studies. These earlier 
studies used a variety of outcome measures, from pain scales to joint range of movement and 
mobility and oedema. 
Lussignoli et al. (1999) conducted a study on rats to determine the effect of Traumeel S on 
blood-induced inflammation, whereby 0.1 ml of homologous blood was injected into the hind paw, 
to facilitate the development of oedema. The results showed that Traumeel S appeared to 
speed up the healing process. This study was, however, designed for rats and the inflammation 
was induced through the re-admission of previously collected blood. The only inflammatory 
markers, which were measured and assessed were serum IL-6 and oedema both of which were 
found to be significantly reduced with Traumeel S use (p < 0.05). 
In other studies on whole blood cultures, Traumeel S has been shown to elevate levels of TGF-P, 
an anti-inflammatory cytokine (Heine and Schmotz, 1998), while in vitro studies have shown that 
Traumeel S is non-cytotoxic to granulocytes, lymphocytes, platelets and endothelial cells and 
the defence mechanisms of these cells are not impaired by Traumeel S (Porozov et al., 2004; 
Conforti et al., 1997). 
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The most recent findings, relating to the efficacy of Traumeel S in attenuating systemic markers 
of a post-exercise inflammatory response, are provided by the Sports Research Institute of 
Pretoria University (Jordaan, 2006). This study compared an experimental group receiving a 
combination of Traumeel S tablets and ointment to a control group of subjects who received 
placebo treatment for seven days prior to 45 minutes of downhill running. Unfortunately, the 
only markers relevant to a systemic inflammatory response which were measured were blood 
Cortisol, leukocyte counts and serum CK. The exercise protocol did also not appear to be of 
sufficient intensity to elicit a marked inflammatory response. Although serum CK was modestly 
raised in both the experimental and control subjects 24 hours following the trial, there was no 
significant difference between the two groups. The experimental group did, however, present 
with significantly higher concentrations of Cortisol 48 hours after exercise than the control group. 
No significant difference was observed in leukocyte count between the experimental and control 
groups. 
A more carefully designed in vivo study measuring appropriate indicators of systemic 
inflammatory response, following a more intense eccentric exercise protocol that induces 
muscle damage and an inflammatory response, is thus required. 
2.9. CONCLUSION 
For a drug that is so widely used by endurance athletes, so long in existence, with so little 
scientific evidence supporting its mechanism of action and alleged effects, a comprehensive 
study is required to confirm and validate its effectiveness. 
As far as the researcher is aware, the majority of evidence in favour of the efficacy of Traumeel 
S is subjective in the case of sports and exercise related injuries and in vitro in the case of 
biochemical mechanistic studies. The need for an in vivo study on endurance athletes which 




3.1 ETHICAL APPROVAL AND INSURANCE 
Prior to the commencement of this study, ethical clearance was obtained from the University of 
KwaZulu-Natal (UKZN), Nelson R. Mandela School of Medicine, Biomedical Research Ethics 
Committee, Clearance Number: - E017:05(1). 
Insurance was obtained from Heel (Pty) Ltd. in Germany, to cover the UKZN in the event of 
possible research-related injury to the participant, which may have occurred due to the downhill 
running on the treadmill. 
Each subject read and signed an informed consent form which had been approved by the 
Biomedical Research Ethics Committee of the University of KwaZulu-Natal (Appendix A, B). 
3.2 SAMPLE SELECTION 
The study was limited to 24 men and women (n = 24), aged 20-50 years, who had covered a 
mean of 40-60 km per week in training or who were training a minimum of three times per week 
if participating in team sports, during the six weeks prior to participation in the study. All 
participants volunteered to participate in the study. 
Subject exclusion criteria included: 
(i) Pregnancy (in the case of ladies) 
(ii) Smoking 
(iii) Clinical signs of infection, cardiovascular impairments and diabetes (as 
verified by a medical practitioner) 
(iv) Intake of medication (e.g. analgesics or anti-inflammatory) prior to the 
exercise testing 
26 
(v) Habitual dietary vitamin intake without agreeing to a two-week washout 
period. Subjects were asked to avoid ingestion of caffeine, alcohol, or 
other drugs in the 24 hours before their visits to the laboratory. 
Following baseline laboratory and field-testing, pairs of subjects were matched according to: 
(i) Gender 
(ii) BMI 
(iii) Current training profile 
(iv) Training age 
as well as at least two of the following: 
Foot strike 
VO2 max 
1609m running time and/or best performance over longer endurance 
running events (5km, 10km, half marathon or marathon), within six 
months prior to the study trials. 
3.3 EXPERIMENTAL DESIGN 
Following the provision of informed consent, subjects underwent exercise testing on three 
occasions: one introductory laboratory visit for baseline testing and familiarisation with the 
treadmill, one field visit and one subsequent 90-minute exercise trial (Appendix C). After 
baseline and field-testing, the subjects were matched as described above and then randomised 
to treatment sequences using random number tables. Interventions were coded by Heel (Pty) 
Ltd. in Baden-Baden, Germany prior to being dispatched to South Africa. Neither the subjects 
nor the researchers were aware of which treatment was active and which treatment was placebo. 
The coding was only revealed to the researchers once the study was complete and results were 
available. 
Laboratory Testing 
At the first laboratory visit, the subjects each reported to the laboratory for a pre-study evaluation. 
This included documenting details regarding exercise training status and measurements of basic 
anthropometry, lung function, resting heart rate and blood pressure (Appendix C). Percentage 
body fat was estimated from the sum of biceps, triceps, sub scapular and suprailiac skin folds 
using the technique described by Durnin and Womersley (1974). Lung function, including forced 
vital capacity (FVC) and forced expiratory volume (FEVi) was tested using a Jaeger Mastercope 
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spirometer (Wuerzburg, Germany). A physician examined each subject in order to ensure that 
he was not in possession of any clinical symptoms of upper respiratory tract infection (URTI). 
An incremental exercise test to exhaustion was conducted on a level treadmill to determine their 
peak oxygen consumption (V02peak)-
Subjects were familiarized with the motor driven treadmill (Powerjog GX100, Sport Engineering 
Limited, Birmingham, England) and warmed up for five minutes at a speed of 12 km/hr for men 
and 8 km/hr for women. Thereafter, the running speed was increased by 1 km/hour each 
minute until the subject reached fatigue. The test was terminated once the subjects reached 
two of the following: (i) a rating of 8-10 on the rate of perceived exertion (RPE) scale (ii) an 
estimated maximal age-predicted heart rate (iii) a respiratory quotient (RQ) of > 1.15. The 
highest V02 over a 30-second period was defined as V02 peak-
To measure V02 during the treadmill tests, the Metamax Metabolic Analyser, (Jaeger, 
Netherlands) was used to measure respiratory and metabolic responses during exercise. The 
gas analysers were calibrated using a room air and gas cylinder containing 16% 0 2 and 5% C02 
in nitrogen (Afrox Gas, Durban). The flow volume sensors were calibrated using a 21 calibration 
syringe (Jaeger, Netherlands). Mixed chamber analysis of the expired respiratory gases was 
conducted using a connector facemask and triple V transducer and twin tube. The volume of 
expired air was measured by the triple V sensors and a sample was fed to the gas analyzers via 
the twin tubes. In addition, heart rate was also recorded throughout the test using a polar heart-
rate monitor (Polar Electro OY, Finland) and rating of perceived exertion, according to the 10-
point scale described by Borg (1982), in addition to V02, Pulmonary Ventilation (VE), VC02and 
RQ, were recorded during the last 30 seconds of every phase of the incremental test. 
A regression equation of oxygen consumption vs. power output was derived from the sub-
maximal running speed to determine the running speed corresponding to 75 % V02peak-
Field Testing 
A field visit was conducted at the University of KwaZulu-Natal's sports grounds approximately 
one week before the trial. Springbok athletics coach and consultant, Norrie Williamson 
conducted these assessments. Subjects were required to warm up at a relevant pace and 
thereafter ran a 1609m (four laps) time-trial on the track. Further recording and analysis of past 
and current training practices was conducted, as was analysis of running style in terms of foot 
strike, both while running on an athletics track and down a hill (gradient > -5%). Feedback was 
given to the subjects. Explanation of pre-intervention training and eating procedures was done. 
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The matching of subjects according to their gender, training age, baseline measurements taken 
at the first laboratory visit and their running style, training status and performance time in the 
1609m field test, was completed after the completion of above-described baseline tests. 
Traumeel S and Placebo Trials 
Five days prior to the trial, each subject was required to ingest three Traumeel S or Placebo 
tablets per day. Subjects were requested to dissolve the tablet under the tongue at least 30 
minutes before mealtime (or on an empty stomach) and tablets were taken for the full 
duration of the trial until the last blood sample (72 PE) had been given. 
- The day before the trial, subjects were instructed to avoid any heavy physical exercise. 
On the morning of the trial, the following breakfast was eaten three hours before the trial: 
30g cornflakes, 150m* of low fat milk and 12-15g refined sugar. 
On trial day, the subjects were required to report to the laboratory in the morning three hours 
after consuming a prescribed breakfast. A pre-exercise venous blood sample was obtained 
from an antecubital vein. The exercise protocol consisted of a -6% downhill run for 90 
minutes on a motorized treadmill, which had been adjusted to the appropriate downhill 
gradient. The running speed was set at that which corresponded to 75% of the individual 
maximal oxygen consumption (75% V02max)> as determined during the baseline testing and 
field visit. During each actual trial run, the participants were required to wear a heart rate 
monitor to allow for continuous recording of their heart rate. At 30 minutes and at one hour 
into the run, the subjects were allowed a 2-minute reduction of workload to 50% V02max. 
ensuring an easy water intake from a bottle containing 500 m* of water. The subject was 
required to consume the total amount of water. Music was available to entertain the runners 
on the treadmill and free communication between runners and research assistants was 
encouraged. 
On completion of the exercise trial, a 30ml blood sample was drawn from an antecubital vein 
immediately after the trial. 
Post-Trial Recovery 
At 24, 48 and 72 hours following the trial, subjects were requested to return to the exercise 
laboratory, at the same time each day as their IPE blood sample was taken, to attain further 
blood samples and to record subjective ratings of DOMS. Subjects were also requested not to 
resume training during this post-trial period of three days. 
Subjective ratings of muscle soreness were determined at the beginning of each day following 
the Traumeel S and Placebo exercise trials with a numerical 0-10 scale where 0 = no pain at all, 
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5 = moderate, 10 = severe/maximal pain (Appendix D). The quadriceps, hamstrings and calf 
muscles were assessed under four categories: 
• General pain (subject seated and relaxed) 
• Daily living (walking/moving) 
These subjective ratings of discomfort in the groups of muscles in the four above-mentioned 
categories, as well as the peak rating in one particular muscle group, were expressed as a 
mean ± standard deviation (SD). 
Haematoloqical Analysis and Adjustments 
All post-event blood samples were obtained at the same time of day to avoid the influence of 
diurnal rhythms on blood Cortisol concentrations. The participants were asked to refrain from 
any strenuous exercise during the three days following the trial day. 
Full blood counts including differential leukocyte and platelet counts were performed on K3 -
ethylene diaminetetra-acetic acid (EDTA) treated specimens using standard haematological 
procedures on an automated STKS model (Coulter Electronics Inc., Hialeah, Florida, USA). 
Plasma volume changes were determined from pre- and post-race haematocrit and 
haemoglobin concentrations according to the method of Dill and Costill (1974) in order to 
estimate changes in blood volume, which occurred following participation in the 90-minute 
downhill trial. All concentrations of the blood cell parameters were adjusted for exercise-
induced changes in blood volume. 
The following mathematical equation originally developed by Dill and Costill (1974) was used to 
calculate the percentage change in plasma volume (IPE versus PRE and 24 PE versus IPE): 
% A PV = HbpRE w 1 — HctpR 
A - 1 
HbpR 1 - HctpRE 
x100 
WhereA PV= Change in plasma volume 
PRE = pre-trial sample 
PR = post-trial sample 
Hb = Haemoglobin concentration 
Hct = Haematocrit 
Five ml of the remaining blood was allowed to clot at ambient temperature, the serum separated 
and 0.5m? aliquots thereof stored in Eppendorf tubes at -70°C for later analysis of CRP, CK and 
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Cortisol. The remaining blood was drawn into vacutainer tubes containing EDTA and the plasma 
separated. This was stored at -70°C for later measurement. 
Determination of Serum CK, LDH, Cortisol and IL-6 Concentrations 
Serum was sent to a local Chemical Pathology Laboratory (Global Clinical and Viral 
Laboratories, Jacobs, Durban), and analysed for CK and LDH concentration using a Synchron 
CX, X5Analyser (Beckman Coulter, SA (Pty) Ltd., Halfway House, South Africa). 
Serum Cortisol was assayed using the Gamma Coat radioimmunoassay procedure (AB Advia 
Centaur CPAdviacentaur, Siemens Medical Solutions Diagnostics, Deerfield, USA). 
Plasma IL-6 concentration was determined by sandwich ELISA using a commercial kit 
(eBioScience, San Diego, CA, USA) 
Determination of Serum CRP Concentrations 
An immunoturbidimetric assay (Randox CRP Kit T, Cat No CP 7950, 2002 and CRP Standard, 
Cat No CP1599, Randox Laboratories Ltd., Antrim, UK) was used to determine the 
concentration of CRP in the serum samples. The standard was diluted with 0.9% sodium 
chloride (NaCI) solution in the following geometric series: 















• Well-thawed serum was used undiluted and 20 minutes prior to preparation, both the 
reagents and samples were equilibrated to room temperature. 
• 1.0m* of buffer made up of 4% Polyetheline Glycol, 20mmol/{ Tris/HCL (pH 7.4) and 150 
mmol/t NaCI buffer was added to 100u£/blank standard/undiluted sample and mixed well 
for three minutes to equilibriate. 
• 150u« 0.9% NaCI solution was added to the blank while 150u£ I anti-human CRP was 
added to the sample/standard. After mixing well and covering tubes with plastic cling 
film, they were left to incubate for 15 minutes. After mixing, the absorbance of each 
solution read on a spectrophotometer (Cary IE, Varian, Palo Alto, USA) at a wavelength 
of 340nm. 
• The samples were read in a 1cm light path glass microcuvette at a temperature of 25°C 
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Standard Curve and Calculation of Results 
In order to determine the CRP concentration of the sample, a standard curve, derived from the 
absorbance of standards, was constructed for the assay run. This curve was obtained from the 
following equations, which takes into consideration that the CRP concentration is dependant on 
the batch specific CRP standard, which is chosen. 
CPR concentration of dilution series = assigned value of undiluted standard x dilution factor 
A Asampie/standard = Test Absorbance - Blank Absorbance 
y = 0.017x 
R2 = 0.954 
The A Astandard was plotted against the given CRP concentration of the dilution series and the A A 
of the samples was read off this graph to determine their concentration. 
20 30 40 
CRP Concentration (mg/dL) 
50 60 
Figure 3.1: Correlation between CRP concentration (mg/dL) and change in absorbance (nm) 
Measurement of Serum Myeloperoxidase 
An in vitro enzyme-linked immunosorbent assay (ELISA) (Immundiagnostik AG, Lot No K6631) 
was used to determine the presence of MPO in the serum samples. The assay utilised the two-
site "sandwich" technique with two selected polyclonal anti-bodies that bind to human MPO. 
Assay standards, controls and prediluted subject samples containing human MPO were added 
to the wells of the microplated that was coated with a high affine polyclonal anti-human MPO 
antibody. The MPO of the subject samples was captured by the antibody which was 
immobilised on the walls of the microtiter wells after the first incubation period of 60 minutes at 
room temperature. Peroxidase-conjugated polyclonal anti-human MPO antibody was then 
added to each microtiter well which formed a "sandwich" of captured antibody - human MPO -
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Peroxidase conjugate. Tetramethylbenzidine (TMB) was used as a substrate for the peroxidase. 
To terminate the reaction, an acidic stop solution was added to the samples. The colour change 
from blue to yellow indicated the presence of MPO in the samples, as the intensity of the yellow 
colour is directly proportional to the concentration of MPO in the sample. The MPO present in 
the samples was directly determined from a dose response curve of the absorbance unit (optical 
density (OD) at 450nm) versus concentration. This curve was generated using the values 
obtained from the standard and the A A of the samples was read off this graph to determine their 
concentration. 
MPO concentration of dilution series = assigned value of undiluted standard x dilution factor 
A ASampie/standard = Test Absorbance - Blank Absorbance 
y=12828x2+1219.1x 
R2 = 0.9876 
The A Astandard was plotted against the given MPO concentration of the dilution series and the A A 
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Figure 3.2: Correlation between MPO concentration (ng/m{) and change in absorbance (nm) 
3.4 STATISTICAL ANALYSIS 
Data was analysed in SPSS version 15.0 (SPSS Inc., Chicago, Illinois, USA). A p value < 0.05 
was considered as statistically significant. Baseline and field trial outcomes were compared 
between the two groups using paired f-tests as well as Wilcoxon Signed Rank Tests. Qualitative 
descriptions of foot strike pattern were categorised into three pattern types and the McNemar-
y=12828x2 + 1219.1x 
R2 = 0.9876 
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Bowker Chi Square Test was used for comparison of the paired foot strikes. Repeated 
measures analysis of variance (ANOVA) testing was used to compare quantitative normally 
distributed outcomes over time between the experimental (TRS) and placebo-control (PLAC) 
groups. Wilks' Lambda was used as test statistic with a Simple Contrasts post hoc correction to 
determine the time-point of the significant differences between treatments. Variables that were 
not normally distributed were log transformed. Significant time-group interactions indicated 
significant treatment effects. Profile plots were generated to examine trends. There was very 
little missing data, but for some outcomes, the final time point result was missing in a few (up to 
four) cases. In this case, repeated measures ANOVA was conducted on four time points as well 
as five and the results were compared. If there was no difference in the conclusion then the five 
time-point comparison was reported. For the DOMS analysis, the average of the three muscle 
types and modes were computed for each day. Repeated measures ANOVA was performed on 




4.1. SUBJECT CHARACTERISTICS 
Of the 24 subjects who fully complied with all inclusion criteria, 10 were women and 14 were 
men with the age of the subjects ranging from 19 to 50 years. The BMI of the total sample 
ranged from 19.6 to 31.6 kg/m2, while the body fat percentage ranged from 7.5 to 27.7%. Table 
4.1 depicts the mean (± SD) physical characteristics of the two gender-matched groups on 
Traumeel S (TRS) and Placebo (PLAC). 
Table 4.1: Mean ± SD physical characteristics of subjects in the TRS (n = 12) and PLAC (n = 12) groups 




% Body Fat* 
BMI (kg/m2) 
28.8 ± 7.8 
171.7 ± 11.5 
69.7 ±13.4 
15.1 ±4.2 











* Derived from the sum of triceps, biceps, suprailiac and subscapular skin folds 
" Paired Mests TRS vs. PLAC 
Subject characteristics were analysed both parametrically using paired f-Tests and non-
parametrically using Wilcoxon Signed Rank tests. Irrespective of the analysis used, the two 
groups did not differ significantly in terms of age, stature, mass, % body fat and BMI (p > 0.05). 
4.2. BASELINE MEASUREMENTS 
During the maximal exercise test, the maximal heart rate ranged from 170 to 196 beats per 
minute (bpm) and the V02 peak from 42.0 to 63.8 m£/kg/min. The maximum respiratory 
exchange ratio (RER) ranged from 1.02 to 1.28 and the VEmax from 76 to 138 f/min. The range 
of the FVC was from 2.57 to 7.911 and the FEVi ranged from 2.05 to 5.911. The mean (± SD) 
results of the above-mentioned measures in the TRS and PLAC groups are presented in Table 
4.2. 
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Table 4.2: Mean ± SD baseline test measurements of subjects in the TRS (n = 12) and PLAC (n = 12) groups 
Variable TRS PLAC p value* 
V02 peak (mt/kg/min) 54.00 ± 6.48 
RER 1.15 ±0.07 
Maximum Heart Rate (bpm) 182 ± 7.85 
Resting Heart Rate (bpm) 62 ± 7.04 
VE(«/min) 108.4 ±18.0 
FVC(«) 4.67 ±1.09 
FEVi (I) 4.00 ± 0.89 
"Paired (-tests TRS vs. PLAC 
Data were analysed parametrically and non-parametrically and again, both confirmed that the 
gender-matched subjects within the two groups did not differ significantly in terms of the 
parameters listed in Table 4.2. 
50.37 ± 4.66 
1.14 ±0.09 
185 ±9.48 











4.3. FIELD AND TRAINING PROFILE 
Table 4.3 displays the comparative field and training profiles of the PLAC and TRS groups. 
Subjects within the two groups were also well matched in this regard as is depicted by marginal 
differences in the means ± SD, all of which were not statistically significant (p > 0.05). 
Table 4.3: Mean ± SD field and training profile measurements of the subjects in the TRS (n = 12) and PLAC (n = 12) 
groups 
Variable TRS PLAC p value* 
Ave Running Distance (km/week) 
Number of Years Running 
1609m Time (min) 
5km Time (min)* 
10km Time (min)* 
Half Marathon Time (min)* 
Marathon Time (min)* 
* 5km; n = 8; 10km: n = 7; Half marathon: n = 15; Marathon: n = 8 
" Paired f-tests TRS vs. PLAC 
The different foot strike patterns and the prevalence (n; %) of each pattern in both the control 




22.20 ± 5.22 
43.8 ±9.18 
100.7 ±9.99 
233.0 ± 29.5 
40.5 ±18.9 
10.72 ±6.05 
6.31 ± 0.97 
20.00 ± 0.00 
41.00 ±1.41 
102.0 ±17.6 








4.5. MARKERS OF MUSCLE CELL DAMAGE 
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4.5.1. Serum Lactate Dehydrogenase 
The mean ± SD of the serum LDH concentrations obtained before and following the trial are 
shown in Figure 4.1. The mean ± SD LDH concentrations of all subjects (n = 24; top), adjusted 
for PV changes, peaked immediately post-trial reaching a significantly elevated mean value of 
555.3 ± 137.3 lU/t (p < 0.001) and ranged from 368 to 847 lU/t. The LDH concentrations 
declined steadily for the duration of the recovery, returning to pre-exercise levels at 72 hours 




• M i l 
PRE IPE 48 PE 72 PE 
Figure 4.1: Mean ± SD LDH concentrations of complete sample (n = 24; top) adjusted for PV changes and 
TRS (n = 12) and PLAC (n = 12) groups (bottom) prior to and following participation in the 90-
minute downhill treadmill run 
* p < 0.05 Paired /-tests vs PRE 
# p < 0.05 Time-group interaction, repeated measures ANOVA, Wilks' Lambda Test Statistic 
** p < 0.05 Simple contrasts post hoc comparison vs. PRE between groups at time point 
The comparative serum LDH concentrations for both the TRS and PLAC groups are also shown 
in Figure 4.1 (bottom). In the TRS group, the LDH increased maximally immediately following 
the trial reaching a mean concentration of 620.2 ± 146.4 IU/€, while the PLAC group reached a 
38 
mean concentration of 496.3 ± 107.8 \\J/l at 24 PE. When the plasma volume adjusted 
concentrations are expressed relative to the concentrations at the previous time point (Table 4.6) 
and baseline values (Figure 4.2), the differences between the two interventions are however, not 
statistically significant (p = 0.536). 
Table 4.6: Mean ± SD differences in LDH concentrations (lU/f) prior to and following participation in the 90-minute 
downhill run in the TRS (n = 12) and PLAC (n = 12) groups 
Time Difference TRS PLAC p value* 
IPE vs. Pre Trial 
24 PE vs. IPE 
48 PE vs. 24 PE 







-38.8 ± 49.2 





' Paired f-tests TRS vs. PLAC 
Figure 4.2: 
IPE-PRE 24PE-PRE 48PE-PRE 72PE-PRE 
Time 
'—•— PLAC - • — TRS I 
Mean changes* in serum LDH concentrations in the TRS group (n = 12) and PLAC groups 
(n = 12) following participation in a 90-minute downhill run 
* Adjusted for pre-trial concentration 
4.5.2. Serum Creatine Kinase 
The mean ± SD serum CK concentrations for the total sample (n = 24) is depicted in Figure 4.3 
(top). The CK concentration rose significantly in response to 90 minutes of downhill running 
(p < 0.001), peaking at 24 hours post exercise (1474.2 ± 1172.3 III/*) and remained significantly 
elevated in the 48 PE and 72 PE serum samples (p < 0.05) despite relatively large variances 
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Figure 4.3: Mean ± SD CK concentrations adjusted for plasma volume changes of complete sample (n = 24; 
above) and TRS (n = 12) and PLAC (n = 12) groups (below) prior to and following participation in 
the 90-minute downhill treadmill run 
* p < 0.05 Paired f-tests vs PRE 
** p< 0.05 Simple contrast post hoc comparison vs. PRE between groups at time point 
As is shown in Figure 4.3 (bottom) the time effect between the TRS and PLAC groups was 
highly significant (p < 0.001), but the group-time interaction did not reach statistical significance 
(p = 0.398; repeated measures ANOVA, Wilks' Lambda test statistic). Simple contrasts post-
hoc analyses revealed that the absolute CK concentration differences were only statistically 
significant at the IPE time point (p = 0.04). 
When the concentrations are expressed relative to the concentrations at the previous time point 
(Table 4.7) and are adjusted for baseline values (Figure 4.4), the differences between the two 
interventions are also not statistically significant (p > 0.05). 
Table 4.7: 
PLAC (n = 
Mean ± SD differences 
12) groups 
Time Difference 
in serum CK concentrations 
TRS 
(IU/Q adjusted for PV changes in the TRS (n = 12) and 
PLAC p value** 
IPE vs. Pre Trial 
24 PE vs. IPE 
48 PE vs. 24 PE 
72 PE vs. 48 PE 
88.4 ± 45.5 
1394.8 ±1224.6 
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Mean changes* in CK concentrations in the TRS (n = 12) and PLAC groups (n = 12) following 
participation in a 90-minute downhill run 
* Adjusted for pre-trial concentration 
4.6. DELAYED ONSET MUSCLE SORENESS 
As depicted in Figure 4.5 the mean DOMS score peaked at Day 2 post trial and declined 
steadily thereafter. The majority of subjects reported that pain was elicited during activities and 
walking as opposed to at rest. The muscle groups most affected were the quadriceps muscles, 
followed by the calf muscles. The hamstring muscle group was the least affected. Five subjects 
reported pain in all muscle groups. The overall means of the DOMS scores over the four days 
following the trial were analysed using repeated measures ANOVA tests not did not reveal a 
significant group-time interaction over the three days post exercise (p = 0.68). The difference 
between the two groups was only significant on the 2nd day post trial. 
Figure 4.5: Mean ± SD reported peak DOMS scores of the TRS (n = 12) and PLAC (n = 12) groups 
following participation in a 90-minute downhill run 
* p < 0.05 Paired f-tests, TRS vs PLAC 
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The peak DOMS score in each subject during the three-day recovery period the score was 
compared with the percentage change in measured serum CK concentrations from PRE to 24 
PE (Figure 4.6). The correlation between these two indicators of exercise-induced muscle cell 
damage were statistically significant (r = 0.33, p < 0.05). 
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y = 0.0013x + 6.6607 
r = 0.33 
1 
Figure 4.6: 
500 1000 1500 2000 2500 
% Change in Serum CK concentrations 
3000 
Peak DOMS score versus % change in serum CK concentrations (n = 26) during the 24 hours 
after completion of the 90 minute running trial 
4 .7 . HAEMATOLOGICAL ANALYSES 
The time effect in the red blood cell (RBC) indices before and after the 90-minute downhill run 
as well as the plasma volume changes between time-points are shown in Figure 4.7. There was 
a significant time-effect over the three days in each of the indices (p < 0.05). 
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4.7.1. Red Blood Cell Indices & Plasma Volume Changes* 
I 
Figure 4.7: 









Changes in RBC indices before and after 90 minutes of downhill running (n - 24) 
#p < 0.01; Repeated measures ANOVA, time effect 
* Calculated using the formula of Dill and Costill (1974) vs.PRE 
The comparative red blood cell indices for the experimental and placebo-control groups are 
presented in Table 4.8. No significant difference was found between the two groups in terms of 
RBC count, haemoglobin concentration (Hb), haematocrit (Hct) and plasma volume (PV) 
changes. Exercise-induced increases in these red blood cell indices were consistent between 
the two groups, resulting in significant decreases in PV following the 90-minute trial (p < 0.001; 
IPE) with subsequent increases at 24, 48 and 72 hours post-trial when compared to the pre-trial 
(Figure 4.7). 
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Table 4.8: Mean ± SD RBC indices in TRS (n = 12) and PLAC (n = 12) groups before and after 90 minutes of downhill 
treadmill running at the 5 time-points 
Pre - Trial 









4.96 ± 0.40 
4.89 ± 0.43 
43.8 ± 3.62 
43.7 ± 4.20 
15.1 ±1.42 
14.6 ±1.70 






5.09 ± 0.40 
5.01 ± 0.41 
44.6 ± 3.32 




- 4.80 ± 3.59 
24 PE 
4.76 ± 0.38 
4.75 ± 0.41 
42.0 ± 3.07 
42.3 ± 4.00 
14.6 ±1.29 
14.3 ±1.79 
3.60 ± 5.03 
2.59 ± 3.78 
48 PE 
4.78 ± 0.40 





7.20 ± 7.70 
5.94 ± 5.05 
72 PE 
4.80 ± 0.25 
4.65 ± 0.46 










p = 0.96 
p < 0.001 
p = 0.10 
p < 0.001 
p = 0.71 
p < 0.001 
p = 0.98 
# Repeated measures ANOVA, Wilks' Lambda Test Statistic 
" Versus PRE - calculated using formula of Dill and Costill (1974) 
4.7.2. White Blood Cell Indices 
The time effect in the white blood cell (WBC) indices in the full study sample (n = 24) before and 
after the 90-minute downhill run are shown in Figure 4.8, while the comparative white blood cell 
indices for both the experimental and placebo-control groups are shown in Table 4.9. 
The white cell count (WCC) increased significantly at both the IPE (p < 0.001) and at 24 PE 
(p < 0.05) when compared to the pre-trial WCC values. The neutrophil counts were significantly 
increased at the IPE interval (p < 0.001) and returned to near pre-trial values within 24 hours. 
No time or interaction effect was observed in the lymphocyte counts. Significant monocytosis 








Figure 4.8: Mean 
WBC 
indices of 
subjects (n = 24) 




*p < 0.05 Paired 
/-tests vs PRE 





Table 4.9: Mean ± SD absolute differential WBC counts* in TRS (n = 12) and PLAC (n •• 
the 90 minute downhill running trial at the 5 time points. 
12) groups before and after 




White Cell Count (109/€) 
TRS Group 7.02 ±2.31 9.13 ±3.08 7.61 ± 1.99 7.40 ±2.45 
PLAC Group 7.07 ±1.85 9.27 ±2.00 7.39 ±1.88 7.35 ±1.80 
Neutrophil Count (109/€) 
TRSGroup 4.19 ±1.80 6.22±2.76 4.65 ±1.62 4.54 ±1.92 
PLACGroup 4.06 ±1.63 6.09 ±1.90 4.19 ±1.53 4.21 ± 1.43 
Lymphocyte Count (109/ €) 
TRSGroup 1.89 ±0.64 2.00 ±0.82 2.03 ±0.72 1.92 ±0.60 
PLACGroup 2.12±0.54 2.20±0.59 2.21 ± 0.58 2.23±0.77 
Monocyte Count (109/€) 
TRSGroup 0.43 ±0.15 0.47 ±0.14 0.43 ±0.10 0.41 ±0.10 
PLACGroup 0.47 ±0.17 0.54 ±0.17 0.46 ±0.19 0.43 ±0.16 
Eosinophil Count (109/€) 
TRSGroup 0.21 ±0.12 
PLACGroup 0.19 ±0.18 
Basophil Count (109/€) 
TRSGroup 0.11 ±0.09 0.11 ±0.09 0.09 ±0.05 0.10 ±0.07 
PLACGroup 0.11 ±0.03 0.09 ±0.05 0.08 ±0.05 0.10 ±0.06 
0.13 ±0.12 0.22 ±0.13 0.20 ±0.13 
0.15 ±0.16 0.23 ±0.17 0.21 ± 0.08 
6.92 ± 2.03 









0.09 ± 0.06 
0.12 ±0.05 
p = 0.008 
p = 0.91 
p = 0.003 
p = 0.94 
p = 0.28 
p = 0.94 
p = 0.04 
p = 0.82 
p = 0.08 
p = 0.12 
p = 0.68 
p = 0.40 
* all post trial concentrations are adjusted for PV changes 
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Changes in WCC (top left), neutrophil (top right) and monocyte (left bottom) and eosinophil 
(bottom left) concentrations in the TRS (n = 12) and PLAC groups (n = 12) before and after the 
90-minute treadmill trial 
* p < 0.05 Paired f-tests vs PRE 
# p < 0.05 Time-group interaction, repeated measures ANOVA, Wilks Lambda Test Statistic 
4.8. SERUM MYELOPEROXIDASE 
The mean ± SD serum MPO concentrations for all subjects are depicted in Figure 4.10. MPO 
was significantly increased immediately post trial for both groups of subjects (p < 0.05) and 





PLAC — • — T R S 
Mean ± SD serum MPO concentrations of complete sample tested (n = 14; top) adjusted for PV 
changes and of the TRS (n = 7) and PLAC (n = 7) groups (bottom) before and after participation 
in the 90-minute trial 
* p < 0.05 Paired f-tests vs PRE 
# p < 0.05 Time-group interaction, repeated measures ANOVA, Wilks' Lambda Test Statistic 
** p < 0.05 Simple contrast post hoc comparison vs. PRE between groups at time point 
As presented in Table 4.10, comparatively the TRS group reached a mean increase of 227.3 ± 
130.7 ng/mt, which is significantly higher (p > 0.05) than the mean increase of 137.2 ± 71.9 
ng/nrrt in the PLAC group. 
Table 4.10: Mean ± SD serum MPO concentrations (na/mf) in both the TRS (n = 7) and PLAC (n --
and after 90 minutes of downhill running (n = 14) 
Time TRS PLAC 
= 7) groups before 
p value** 
Pre Trial 
Immediately Post Trial 




59.4 ± 20.7 





' Paired f-tests TRS vs. PLAC 
As is shown in Figure 4.11, when the data were, however, expressed relative to the 
concentrations at the previous time point, differences between the two interventions were only 










IPE 24 PE 
IPLAC HTRS 
Mean changes in MPO concentrations adjusted for pre-trial concentration in the TRS (n = 7) and 
PLAC groups (n = 7) following participation in a 90-minute downhill run 
* p < 0.05 Simple contrast post hoc comparison between groups at time point 
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Absolute Neutrophil Concentration (10^9/1.) 
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Absolute neutrophil concentrations (10 II) in whole blood versus MPO concentration (ng/mf) in 
serum (n = 28). 
The distribution and correlation between absolute neutrophil concentrations (109/£) in whole 
blood versus MPO concentration (ng/mt) in serum is graphically presented in Figure 4.12 
(n = 28; r = 0.28; p = 0.07). 
4.9. INTERLEUKIN-6 
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The mean change in plasma IL-6 concentration for all subjects is shown in Figure 4.13. Plasma 
IL-6 concentrations were significantly increased immediately after the trial for all subjects 
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ST 24 PE 48 PE 72 PE 
Time 
—•—PLAC —•— TRS 
SD plasma IL-6 concentrations of subjec 
the TRS (n = 12) and PLAC (n = 12) groups (bottom) before and after participation in the 90-
minute trial at 5 time points 
* p < 0.05 Paired Mests vs PRE 
As presented in Table 4.11, the TRS group reached a mean increase of 8.89 ± 5.43 mg/f, while 
the PLAC group reached a mean increase of 12.31 ± 14.04 mg/L Both groups peaked 
immediately following their participation in the 90-minute trial and the difference between the two 
groups was not statistically significant (p > 0.05). 
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Table 4.11: Mean ±SD IL-6 concentrations (mg/£) in the TRS (n= 12) and PLAC (n= 12) groups prior to and 
following 90 minutes of downhill running at the 5 time points 
Time TRS PLAC p value* 
Pre Trial 
Immediately Post Trial 
24 Hours Post Trial 
48 Hours Post Trial 
72 Hours Post Trial 
1.82 ±1.42 
8.89 ± 5.43 




12.31 ± 14.04 
2.52 ± 2.78 
3.40 ± 2.70 






' Paired /-tests TRS vs. PLAC 
4.10. SERUM CORTISOL 
Figure 4.14 graphically displays changes in serum Cortisol concentrations for the complete 
sample (top) as well as the TRS and PLAC groups (bottom). The TRS group increased to a 
peak of 754.2 ± 340.5 nmol/t while the control group reached a peak of 600.6 ± 148.4 nmol/t 
(p < 0.001). In both groups, the decline in serum Cortisol concentrations was significant at 24 
hours (p < 0.001), thereafter the decline tapered off and by 72 hours, both groups had returned 


















Figure 4.14: Mean ± SD serum Cortisol concentrations of the complete sample (n = 24; top) adjusted for PV 
changes and in the TRS (n = 12) and PLAC (n = 12) groups (bottom) before and after 90 
minutes of downhill running on a treadmill * p < 0.05 Paired f-tests vs PRE 
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Repeated measures ANOVA revealed that the time effect was highly significant (p < 0.001) in 
both treatment groups, but the group-time interaction did not reach statistical significance 
(p = 0.167). Simple contrasts post hoc analyses verified these findings at each of the time 
points. 
Table 4.12 presents the mean ± SD for the experimental and placebo-control groups in terms of 
the serum Cortisol concentrations at each of the five time points. 
Table 4.12: Mean ± SD serum Cortisol concentrations (nmol/t) in the TRS (n = 
and after a 90-minute downhill run at the 5 time points 
Time TRS 
12) and PLAC (n = 
PLAC 
= 12) groups before 
p value** 
Pre Trial 
Immediately Post Trial 
24 Hours Post Trial 
48 Hours Post Trial 
72 Hours Post Trial 
419.8 ±209.8 














"Paired (-tests TRS vs. PLAC 
When the data are expressed relative to the concentrations at the pre-trial time point, 
differences between the two interventions are not statistically significant (p > 0.05), as shown in 
Figure 4.15. 
Figure 4.15: 
IPE-PRE 24PE-PRE 48PE-PRE 72PE-PRE 
• Time 
—•— PLAC -m- TRS 
Mean changes* in serum Cortisol concentrations in the TRS group (n = 12) and PLAC groups 
(n = 12) following participation in a 90-minute downhill run 
* Adjusted for pre-trial concentration 
« s * | " 
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4.11. C-REACTIVE PROTEIN 
The mean and standard deviations of the CRP concentrations for all subjects (n = 24) obtained 
before and following the trial are shown in Figure 4.16. The CRP concentrations peaked at 24 
hours following the trial reaching a mean value of 10.9 ± 4.0 ng/mi. Thereafter the CRP 
concentrations declined steadily, returning to the pre-trial levels by 72 hours following the trial. 
Figure 4.16: 
PRE 
24 PE 48 PE 72 PE 
Time 
IPE 24 PE 
Time 
48 PE 72 PE 
-PLAC -TRS 
Mean ± SD CRP concentrations of subjects (n = 24; top) adjusted for PV changes and of TRS (n 
=12) and PLAC (n = 12) groups (bottom) before and after participation in a 90-minute downhill 
run in the 5 time points. 
* p < 0.05 Paired Wests vs PRE 
The comparative CRP concentrations for both the experimental and control groups are also 
shown in Figure 4.16 and these values are presented Table 4.13. In both groups, the CRP 
concentrations increase maximally at 24 hours post trial with the experimental group reaching a 
mean increase of 10.2 ± 3.3 ng/m{ while the placebo-control group reached a mean increase of 








Table 4.13: Mean ± SD CRP concentrations (nq/mt) in the TRS in = 
participation in the 90-minute downhill treadmill trial 
Time TRS 
= 12) and PLAC (n = 12) groups before and after 
PLAC p value** 
Pre Trial 
Immediately Post Trial 
24 Hours Post Trial 
48 Hours Post Trial 
72 Hours Post Trial 
6.9 ± 3.4 
7.3 ±2.7 
10.2 ±3.3 
9.7 ± 3.6 
8.1 ± 4.6 
8.9 ± 3.5 
8.3 ± 2.8 
11.5 ±4.6 







' Paired (-tests TRS vs. PLAC 
4.12. THE RELATIONSHIP BETWEEN SERUM CORTISOL, CRP AND IL-6 CONCENTRATIONS 
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Serum Cortisol Concentration (nmol/L) 
y=14.134x + 309.17 
r = 0.22 
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C 30 
y = -0.162x +5.6131 
r = 0.09 
Serum CRP Concentration (ng/ml) 
Figure 4.17: Plasma interleukin-6 concentrations (ng/mt) versus serum Cortisol concentration (nmol/t) 
(n= 120; top left). 
Serum Cortisol concentrations (nmol/t) versus serum CRP concentration (ng/mt) (n = 120; top 
right). 
Plasma interleukin-6 concentrations (ng/mt) versus serum CRP concentration (ng/mt) (n = 120; 
bottom left). 
The distribution and correlation between plasma IL-6 concentrations (ng/mt) and serum Cortisol 
concentration (nmol/£); serum Cortisol concentrations (nmol/t) and serum CRP concentration 
(ng/mt); and plasma interleukin-6 concentrations (ng/mt) and serum CRP concentration (ng/mt) 
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is graphically presented in Figure 4.18 (n = 120). Table 4.14 presents the r-values for these 
correlations between IL-6, serum Cortisol and serum CRP. 
Table 4.14: Co-efficients of correlation between plasma IL-6, serum Cortisol and serum CRP 
Relationship 
Plasma IL-6 versus serum Cortisol 
Serum Cortisol versus serum CRP 
Plasma IL-6 versus serum CRP 





p > 0.05 
p>0.05 
p>0.05 




The aim of the study was to establish whether the administration of Traumeel S during the five 
days before participation and three days following participation, significantly attenuates the 
systemic markers of the inflammatory response, following a 90-minute downhill running trial. 
This was achieved by measuring and analysing DOMS, WBC indices, serum CK, LDH, Cortisol, 
CRP, MPO and IL-6 concentrations immediately before and during the three day post-trial 
period. 
As decoding of the prescribed tablets only occurred after completion of the trial and provision of 
the results to Heel (Pty) Ltd. in Germany, the study was strictly a double-blinded one. The 
design of the study is therefore a strength of the work. 
Due to the possibility of the repeated bout effect being a large confounder following the first 
exercise trial which involved downhill running and a large eccentric component (Nosaka et a/., 
2005; McHugh, 2003; Nosaka and Newton, 2002; Stupka era/., 2001), it was, unfortunately, not 
possible to conduct a cross-over study. In order to eliminate a training effect as a potential 
confounder in the study, this double-blind, placebo controlled study was therefore designed 
using pairs of runners who were matched according to gender, BMI, training history, training age 
as well as performance level (i.e. best times for the 1609m time trial, 5km, 10km, half marathon, 
marathon and ultramarathon) and/or foot strike in order to ensure sufficient external validity. 
The success of this matching was confirmed by parametric and non-parametric statistical 
analyses which revealed the absence of a significant difference between the two sets of gender-
matched pairs in each of the parameters assessed during the baseline tests, field tests and 
treadmill trials. In terms of study design, it was felt that the matching of the athletes was 
superior to the alternative option of using two randomly selected samples, which in the case of 
the small sample size, may have resulted in large differences between the experimental and 
placebo-control groups and hence threatened the validity of the results. 
55 
5.1. SUBJECT CHARACTERISTICS AND MATCHING 
This is the first study of this nature to have been completed on endurance athletes. Due to 
financial constraints, the data are however limited to 12 runners on the active substance and 12 
runners on the placebo. 
This trial required a large amount of commitment from the subjects; they needed to adapt their 
training programmes, take their tablets, complete both a laboratory and baseline field-testing as 
well come into the laboratory on four occasions to provide blood samples following the 90-
minute downhill run on the treadmill. As the subjects were not being paid to participate in the 
study (minimal funding was available), it was difficult to obtain full compliance from the subjects. 
The feedback which they received from the field and laboratory test results were the only 
incentives to participate in the study (Appendix E). 
In terms of anthropometric measurements, the overall mean (± SD) BMI of the 24 subjects was 
23.6 (± 2.9) kg/m2 which falls within the acceptable range of 20 - 25 kg/m2. The mean (± SD) 
percentage body fat of 16.7 (± 4.5) was slightly above the range of 6% -15% of body fat which 
is reported by Wilmore (1983) for male endurance athletes. The lack of statistical significance in 
the difference between the subject characteristics of the groups (Table 4.1), confirms that the 
two gender-matched groups were also well-paired in terms of age, stature, mass, BMI and 
percentage body fat. Gender matching was regarded as imperative in order to control for the 
possibility of a protective effect of oestrogen (Amelink et a/., 1990). 
5.2. BASELINE MEASUREMENTS 
Although the participants of this study cannot be classified as elite athletes, who have been 
described by MacFarlane et al. (1991) as possessing a V02 max in excess of 74.7 (± 1.43) 
mt/kg/min in elite athletes, a combination of the results of the above-average lung function, low 
resting heart rate, VE max, maximum RER as well as V02 peak achieved during the incremental 
maximal test to exhaustion on the treadmill confirms that the subjects used in this study were 
healthy, well-trained athletes of above-average endurance capacity. The mean (± SD) V02 peak 
of the subjects was 52.7 (± 5.7) m£/kg/min, which is lower than the V02 max previously reported in 
elite endurance athletes. It is, however, substantially higher than those published for non-
athletes (Wilmore, 1983). 
5.3. FIELD AND TRAINING PROFILE 
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The mean average training distance and number of years of running (training age) were 
marginally higher in the PLAC group, as was the mean performance time for the 1609m time-
trial. However, as was the case in the 5km, 10km and marathon times, there was no significant 
statistical difference with respect to the performance profile of the PLAC and TRS groups (Table 
4.3). 
In terms of training status, the subjects were matched according to average training distance 
and distance and training age and this is reflected in the means ± SD of the two groups which 
are not statistically different (Table 4.3). 
It can therefore be concluded that the PLAC (n = 12) and TRS groups (n = 12) were well 
matched in terms of physical characteristics, foot strike, and training and performance profiles. 
5.4. TREADMILL TRIAL 
This indicates that although the subjects in the TRS group ran faster (p = 0.03), there was no 
difference between the groups in terms of their RPE, HR, or their mean RPE, mean heart 
rate, % heart rate max and max RPE, indicating that the subjects were undergoing the same 
relative intensity of exercise and making the responses to the two 90-minute treadmill trials 
comparable. 
5.5. MARKERS OF MUSCLE CELL DAMAGE 
Muscle proteins which have been found to leak from the compromised cell membrane, include 
CK (Totsuka et a/., 2002; Clarkson et a/., 1992), myoglobin (Croisier et a/., 1996), FABP 
(Sorichter et a/., 1998), LDH (Overgaard et a/., 2002; Nosaka and Clarkson, 1996) and skeletal 
muscle troponin I (Sorichter et a/., 1997). The present study focussed only on serum LDH and 
serum CK concentrations as representative of this protein group. 
5.5.1. Lactate Dehydrogenase 
In all athletes evidence of exercise-induced muscle damage was provided by an elevation in 
serum LDH concentrations which was recorded in the IPE samples. This reached a mean peak 
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value of 555.3 ± 137.3 IU/€ that was outside of the normal clinical range (200 - 500 IU/£) and 
constituted a 44% mean increase from PRE (p < 0.001). This confirms the findings in the 
literature which are consistent in reporting peak LDH concentrations in serum immediately post-
exercise (Semple et al., 2007; Simpson et al., 2006; Armstrong, 1990). 
The response to the downhill running protocol, however, differed between athletes. It can be 
deduced from the IPE samples that more damage was produced when the running speed and 
impact loading on the eccentrically contracted muscles was greater. The 24 PE samples, 
however, provided evidence of significant recovery (time effect, p < 0.05) despite the statistically 
insignificant difference in the treatment effect (time-group interaction, p > 0.05). 
When comparing the experimental and placebo-control group relative to the LDH concentrations 
at the previous time points (Table 4. 6) and adjusted for baseline values (Figure 4.2), no 
significant difference was observed (p > 0.05), despite the significant time effect (p < 0.001) in 
both groups. 
5.5.2. Serum Creatine Kinase 
Pre-exercise CK values in the current study fell within the normal laboratory ranges (70 - 270 
\\J/l) which were in the range of 66 - 350 IU/€, only one subject fell below the 70 IU/€ and four 
subjects were above the 270 \\J/l range, which indicates that the majority of the athlete's entered 
the trial well rested. 
In the 24 PE samples, serum CK peaked in all of the 24 runners with a mean of 1339.6 lll/t 
(almost 6-fold). This mean peak of serum CK concentration at 24 PE is consistent with previous 
findings of studies examining the effects of exercise-induced muscle damage following downhill 
running (Semple et al., 2007; Jordaan, 2006; Simpson et al., 2006; Peters et al., 2001b). 
Findings of this study also confirmed that peak CK concentrations occur between 12 and 24 
hours post exercise (Semple et al. 2007; Simpson et al., 2006; Peters et al., 2001b; Armstrong, 
1990) as well as large inter-individual differences (Peters et al., 2005). In contrast to the 
findings of Clarkson et al. (1992) who showed that CK concentrations after downhill running only 
increased by approximately 300 \\J/( and those of Jordaan (2006) in which mean serum CK 
concentrations increased only by a mean of 599 ± 448 \U/l, the downhill running protocol used 
in this study resulted in exercise-induced rises as high as 3243 lU/t. This indicates that the 
exercise intensity used for this trial exceeds that used by Clarkson et al. (1992) and Jordaan 
(2006) and demonstrates that it was appropriate in inducing substantial muscle damage in the 
participants. 
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Although the pre- and immediate post exercise concentrations of serum CK were higher in the 
TRS group, no difference between these two groups was apparent 24 hours following the 
exercise trial and the group-time interaction effect was not statistically significant (p = 0.398). It 
could therefore be inferred that there had been more leakage of CK into the blood stream prior 
to the trial, which raises the question of whether the TRS group subjects were as well rested as 
the subjects in the PLAC group. Interestingly the post exercise concentration was highest in the 
TRS group, which confirms the faster running speed and greater impact loading during the 
downhill running (although metabolic response seems to indicate no difference). However, the 
results adjusted for baseline values and presented relative to the previous time point (Figure 4.4) 
indicate no statistically significant overall group-time interaction between the two groups. 
In interpreting these results, it is however, important to take the small sample sizes and 
heterogeneity of the samples into account as these would have lowered the power of the study 
and resulted in a possible type 2 error. Statisticians concur (personal communication, 2008) 
that the faster recovery trend in the TRS group may, however, be meaningful and recommend 
use of a larger, more homogenous sample to verify this. 
Furthermore, previous research findings conducted on the effect of gender differences on CK 
concentrations, report that women had a lower serum CK activity than men (Stupka er al., 2001; 
Clarkson and Hubal, 2001; Amelink et al., 1990). Our findings did not support this as the female 
subjects had lower mean pre-trial CK concentrations which increased almost 8-fold to reach 
peak CK concentrations above those in the men, whose mean CK concentrations only 
increased 5.6-fold. Statistically, the differences were, however, not significant (p = 0.70) which 
is most likely due to the large variation in values of the subjects. 
5.6. DELAYED ONSET MUSCLE SORENESS 
Aoi et al. (2004) described the delayed onset of muscle pain which occurs 24 to 48 hours 
following exercise to which the muscles are not accustomed within the muscle, as a 
distinguishing feature of DOMS. Following the downhill treadmill trial, the majority of athletes 
complained of pain within the 24 to 48 hour timeframe following the trial. Two subjects 
complained of pain immediately after and again 48 hours following the trial, which may indicate 
that they did not comprehend the DOMS concept and most likely initially confused it with muscle 
fatigue following their treadmill trial. 
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As is to be expected, the muscle groups which were reported to be the most affected from the 
downhill trial were the quadriceps muscles and to a lesser extent, the calf muscles. The 
eccentric loading of quadriceps muscle group over a period of 90-minutes supports the work of 
Peake et al. (2005), which proposes that DOMS is the result of microscopic tearing of the 
muscle fibres in response to the load under which they were worked. The hamstrings muscle 
group was the least affected with only a minority of the athletes reporting pain in this group. The 
symptom of DOMS within these muscle groups was elicited predominantly while subjects were 
active, with only two athletes reporting pain while at rest. 
Interestingly, there appeared to be no relationship between the foot strike pattern and the 
muscle group which was affected. However in order to fully investigate the relationship between 
DOMS and foot strike pattern, a comprehensive biomechanical assessment of the lower limb 
and lumbar spine would need to be conducted. In addition to this, complaints of knee, hip or 
lumbar pain, made by the athletes during their trial may have been a result of certain 
biomechanical predispositions, which were not documented. 
It was also interesting to note that although the correlation which exists between the peak 
DOMS score in each subject and the percentage change in measured serum CK concentrations 
from PRE to 24 PE in each subject was relatively low, it did reach statistical significance and 
revealed a trend in that TRS group reported lower DOMS scores from the onset of the trial. A 
shortcoming of this aspect of the research was that pressure pain was not used to measure 
DOMS. 
The findings in this study of significant increases in circulating MPO also supports the theory 
that DOMS could result from phagocyte infiltration and resultant production of ROS and other 
anti-oxidants (Aoi et al., 2005). 
5.7. HAEMATOLOGICAL ANALYSES 
5.7.1. Red Blood Cell Indices 
Should euhydration have been maintained during the 90-minute run, little change in red blood 
cell indices would have been expected. The findings of this study however confirm significant 
increases in RBC, Hb and Hct concentrations in the IPE samples, indicating a degree of 
haemoconcentration. This would imply that the 500 ml of water that each subject was given to 
drink during the 90-minute run, was not sufficient to maintain hydration status. This was 
confirmed by the mean reduction in plasma volume of 4.4% which occurred in the combined 
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sample (n = 24). The changes of 4.8% in PLAC group and 3.9% in TRS group therefore 
necessitated adjustment of all post exercise concentrations of circulating cells, enzymes, 
hormones, and other systemic markers of inflammation. 
Interestingly, the subjects also appeared to have increased their fluid intake post trial as is 
indicated by the increase in their plasma volumes during the three days post exercise. Once 
again, adjustment for plasma volume changes was imperative prior to meaningful comparison of 
circulating concentrations of solutes (including WBC's, hormones, cytokines and enzymes) 
within the two treatment groups. 
5.7.2. White Blood Cell Indices 
As is shown in Figure 4.8 the findings of this study revealed a significant increase (p < 0.001) in 
the PV-adjusted absolute WBC and neutrophil concentrations when comparing pre-trial 
concentrations to immediate post-trial concentrations. This confirms the immediate post 
exercise peak in total WBC, neutrophil and monocyte counts as observed by Smith (1998), 
Nieman (1997) and Pizza et al. (1995). No significant lymphocytosis, monocytosis, eosinophilia 
or basophilia was, however, induced by the downhill running protocol (p > 0.05; Figure 4.8). 
These results confirm the previously described exercise-induced neutrophilia which may be 
related to increasing serum Cortisol concentrations (Pedersen, 1997) and would appear to also 
be indicative of an acute reaction to the microscopic muscle damage inflicted by the downhill 
running protocol. The absence of lymphocytosis is to be expected due to failure of adapted 
immune responses to be triggered immediately post exercise. Interestingly the exercise-induced 
monocytosis only reached border-line significance (time effect: p = 0.51) which indicates 
relatively low mobilisation of monocytes from the bone marrow while the absence of eosinophilic 
and basophilia are to be expected in this relative healthy sample of athletes who would have 
been unlikely to present with asthmatic or parasitic conditions. 
No significant time-group interaction was, however, shown between the TRS and PLAC groups 
in terms of WBC and neutrophil response to the exercise protocol over the three-day period. 
This appears to indicate that TRS does not act by inducing the mobilisation of neutrophils in 
response to microscopic muscle damage. As will be discussed later, the adrenal release of 
Cortisol, well described as trigger of exercise-induced neutrophilia, was also not significantly 
different between the two groups. 
Circulating monocytes have been reported to increase in response to exercise-induced muscle 
injury for up to 48 hours after exercise (Peters et al., 2001a, Malm et al., 1999). However, 
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findings of this study only showed borderline significance (p < 0.051) of the elevated mean 
monocyte concentrations immediately after the exercise trial, and these values had returned to 
pre-trial concentrations within 24 hours. There was no significant (p > 0.05) difference between 
the TRS and PLAC groups with regard to the monocyte concentration response to the exercise 
trial. These findings conflict with those of Jordaan (2006) who reported a significant decrease in 
monocyte activity in the TRS group, but not the control group within 24 hours of recovery. 
Unfortunately differentiation between the monocyte and macrophage sub-populations and 
inclusion of testing for serum prostaglandin levels was not within the scope of this study. This 
information would have been of great interest in interpreting the pro-inflammatory responses to 
the exercise interventions. 
5.8. SERUM MPO 
MPO is a hemoprotein that is abundantly expressed in neutrophils and secreted during their 
activation. As is shown in Figure 2.3, it plays an important role in neutrophil microbiocidal action 
by catalysing chloride ion oxidation to HOCf, a potent antimicrobial agent. In view of the muscle 
damage or expected presence of necrotic/ foreign tissue in primarily the quadriceps muscles (as 
is confirmed by the ± 44% elevation in mean LDH and ± 600% elevation in circulating mean CK 
concentrations following the 90-minute downhill run), increased migration of neutrophils to the 
site of inflammation would be expected. While it was unfortunate that actual muscle biopsy 
samples were not available, the significantly elevated post exercise serum MPO concentrations 
of the group as a whole (n = 24) confirm previous findings of Bury and Pirnay (1995) who 
reported significant elevations of MPO concentrations in plasma following two hours of 
prolonged exercise at 75% V02 max-
Although Suzuki et al. (1999) have shown that the increase in the MPO enzyme activity in 
plasma was proportional to the increase in the number of neutrophils after prolonged exercise, 
our findings did not support this. The low correlation between serum MPO and neutrophil 
concentration is, however, to be expected as post-exercise neutrophil concentrations peak IPE 
whereas serum MPO concentrations peaked 24 hours post exercise. Interestingly when the co-
efficient of correlation between IPE samples was determined, the r-value rose to 0.28 (p = 0.07). 
MPO release into the serum may therefore be a delayed response to exercise-induced 
neutrophilia and activation of the neutrophils which have been drawn to the site of the damaged 
tissue. 
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The key finding of this study is the significantly higher mean ± SD concentration of MPO in 
serum in the 24 PE samples. This is indicative of greater neutrophil activation by MPO which is 
responsible for the catalysis of H202 to HOC* in the TRS group after 24 hours. Although the 
immediate post exercise values were not significantly different, the immunological effect may be 
a delayed one which is not apparent in the IPE blood samples, but in only in the 24 PE blood 
samples. This confirms the findings of Conforti et al. (1997) who hypothesised that the 
mechanism by which Traumeel S is effective in improving recovery rates from muscle cell 
damage is via modulation of neutrophilic production of free radicals during oxidative burst 
activity of the neutrophils. This is the first report of confirmation of this hypothesis via 
measurement of serum MPO concentrations, an indirect marker of neutrophilic oxidative burst 
activity. 
5.9. lNTERLEUKIN-6 CONCENTRATIONS 
The results of this study showed that the IL-6 concentrations significantly increase (p < 0.05) 
from pre-trial values of 2.27 ± 1.67 mg/f to 10.60 ± 10.77 mg/l IL-6 immediately after the 
exercise invention. However, when comparing the experimental and placebo-control groups, 
the difference was not statistically significant (p > 0.05). 
IL-6, in conjunction with other pro-inflammatory cytokines, has been shown to increase blood 
vessel permeability which facilitates the migration of neutrophils and monocytes towards the site 
of tissue damage and inflammation (Roitt et al., 2001). In addition to this, IL-6 is well known for 
its inhibition of pro-inflammatory action via its activation of the adrenal cortex to release Cortisol 
(Nieman, 1997) and stimulation of CRP release (Nieman, 1997), which is evident from the 
delayed increase in CRP concentrations as observed in this study. 
The findings of this study confirm a significant time-effect (p > 0.001). While this was to be 
expected following the downhill running protocol, the peak in post-exercise IL-6 concentrations 
may not have been recorded as, if induced by muscle damage following eccentric exercise, 
previous work has shown that this occurs at between 3-6 hours post-exercise (Peters, 2004). A 
shortcoming of the current study design was that it was not possible to include further blood 
sampling at these time-points. 
The results of this study are in contrast to the findings of Lussignoli et al. (1999) or Conforti et al. 
(1997), which showed an attenuation of the IL-6 response to an inflammatory stimulus in rodents 
following administration of Traumeel S. The failure to confirm a significant time-treatment 
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interaction of this cytokine between the two groups over the three day time-span, may however, 
have been due to the heterogenous response within the two groups and large standard 
deviations, that could have masked any significant effect. 
5.10. SERUM CORTISOL CONCENTRATIONS 
Analysis of the complete sample data (n = 24) showed a 46.9% increase of Cortisol 
concentration to a peak of 706.84 ± 257.81 nmol/t at the 24 hour time point which is lower than 
the findings of Smith (2007) who reported that post-exercise Cortisol concentrations have been 
shown to rise by more than 50% following 60 minutes of downhill treadmill running (gradient -
13.5%) at 75% V02 max and Peters et al. (2001b) who reported increases in Cortisol 
concentrations of ± 200% to mean concentrations of 1179 ± 93,2 nmol/t, following a 90km 
downhill ultramarathon run. 
The increase in serum CK did, however, indicate that the downhill running induced damage 
within the muscles in both the TRS and PLAC groups. Neutrophil activation, oxidative stress 
and the activation of the macrophages with subsequent release of IL-6, is thought to trigger the 
release of Cortisol (Peters et al., 2001a) which has well described anti-inflammatory action. 
Although a greater anti-inflammatory response in the TRS group was observed (754.2 ± 340.5 
nmol/t) when compared to the PLAC group (600.6 ± 148.4 nmol/f) the difference between the 
two groups was not statistically significant (p = 0.97). The most likely reason for the lack of 
significant differences in these largely divergent means are the large intra-group variances as 
reflected by the large standard deviations. It also confirms the results of the IL-6 concentrations 
supporting the suggestion that the treatment effect of Traumeel did not appear to manifest via 
this pathway of anti-inflammatory response. 
5.11. C-REACTIVE PROTEIN CONCENTRATIONS 
The findings of this study are in agreement with those of Semple (2006) and Peters ef al. (2005, 
2001a) which showed that CRP concentrations increase substantially 24 to 48 hours after acute 
exercise and that this increase is often more pronounced following exercise of greater intensity 
owing to the muscle damage which is incurred (Semple, 2006). 
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Clyne and Olshaker (1999) have reported that the values of CRP do not differ between males 
and females and the averages of the general populations are considered normal when less than 
5 mg/l (Gabay & Kushner, 1999). Based on this premise, the pre-exercise CRP concentrations 
for our sample were high (7.88 ± 3.52 mg/l). However, the anti-serum used for the purpose of 
the immunoturbimetric assay is mono-specific for CRP. It has been shown not to cross react 
with other serum proteins under the conditions of the assay, and it is therefore unlikely that 
residual fibrinogen or other plasma proteins that may have remained in the serum, were 
responsible for the unusually high concentrations detected using the commercial kit (described 
in Chapter 3). 
Furthermore, no diurnal or seasonal variation has been observed in CRP values (Pepys, 2003) 
and it has been reported that the levels of CRP in humans are not affected by food intake 
(Semple, 2006). On the other hand, the high general training status of the subjects should also, 
according to the findings of Kelley and Kelley (2006) and Marcell (2005) not have resulted in an 
elevation of baseline CRP concentrations. That the subjects have not rested sufficiently prior to 
the exercise trial is also not likely as this was a requirement of participation in the trial and 
resting Cortisol, IL-6, CK and LDH were low. 
The discrepancy in terms of the high CRP values is therefore difficult to account for. 
The significant time-effect (p > 0.001) with a slight increase in immediate post exercise CRP 
concentration with a peak at 24 hours does however, confirm previous findings of Peters et al. 
(2005, 2001b) and Semple (2006) and indicate the presence of an acute phase response 
following the downhill running protocol. As hepatic release of CRP is a sequel to the release of 
Cortisol by the adrenal cortex and the release of IL-6 by macrophages and muscle tissue (Peters 
et al., 2005), the absence of a group-time interaction in CRP would also be expected. 
5.12. CONCLUSION 
While the IL-6-cortisol-CRP pathway does not appear to be affected by the Traumeel 
intervention in this study, preliminary findings of significantly elevated MPO concentrations at the 
24PE time-point, do suggest evidence of a positive effect in the clearance of debris and 
increased neutrophil activity through enhanced oxidative burst activity. 
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CHAPTER 6 
CONCLUSION AND RECOMMENDATIONS OF FUTURE STUDIES 
Despite shortcomings of this study which include the relatively small sample sizes, low power of 
the study and greater likelihood of type 2 errors occurring, as well as the failure to ensure 
"perfect" matching with minimal genetic differences between pairs and homogeneity within each 
treatment group, this study did highlight an important novel finding. 
Although no significant treatment effects were identified in terms of differential white blood cell, 
IL-6, Cortisol or CRP response to the exercise-induced damage which appeared to be greatest 
in the TRS group, the primary finding of this study is that it provides novel preliminary evidence 
of enhanced serum MPO concentrations at the 24 PE time-point. These are indirect indicators of 
enhanced neutrophil activation and oxidative burst activity with increased production of cytotoxic 
HOC! which is instrumental in facilitating the removal of foreign substances from the muscle 
tissue. Ultimately, this would facilitate healing and accelerate the recovery process. 
The exact mechanism by which this enhanced MPO activation is induced in the Traumeel 
treated group is, however, not clear. On the one hand, it could be due to a direct effect of one of 
the 12 different herbal extracts of which Traumeel S is made up, on the activity of MPO. On the 
other hand, the stimulation may occur at the level of NADPH oxidase or superoxide dismutase 
(SOD). 
Future directions for research would therefore include examining the transcription factors for 
NADPH oxidase, which our research team are currently in the process of undertaking. 
Measurement of SOD concentrations would another research option which would provide an 
independent means of confirming the possible enhancement of pro-inflammatory action of 
Traumeel S, which the findings of this study appear to support. 
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APPENDIX A 
DEPARTMENT OF PHYSIOLOGY 
FACULTY OF HEALTH SCIENCES 
DEPARTMENT OF PHYSIOLOGY 
NELSON R. MANDELA MEDICAL SCHOOL 
SUBJECT INFORMATION SHEET 
Study Title: The effect of an anti-inflammatory homeopathic product on systemk 
narkers of inflammation following downhill running. 
Introduction: This study will investigate the effect of Traumeel. an homeopathic anti-
inflammatory product, on the delayed muscle soreness (DOMS) which occurs following 
Drolonged exercise. As we are interested in establishing the mechanisms which result ir 
this muscle soreness and whether this can be minimized by the use of homeopathic 
preparations, we shall be doing a variety of analyses on your blood samples before anc1 
after exercise. 
Who will qualify to participate in this study? Thirty healthy long-distance athletes 
aged 20 -50 years 
non-smokers, non-diabetic, free of cardiovascular impairments (as verified b> 
medical practitioner) 
not showing clinical signs of infection (as verified by medical practitioner) 
taking no medication (e.g. analgesics or anti-inflammatories) 
covering a minimum of 30 km per week in training 
What will be expected from volunteers in this study? 
You will be asked to: 
- not use any analgesics, anti-infective or anti-inflammatory or Vitamin C 
preparations in addition to the prescribed study supplements for 2 week; 
before and for the duration of the trials. 
- maintain your usual diet for the duration of the trials. 
- maintain the same type of training during the trial period 
- avoid any heavy physical exercise the day before each exercise trial. 
Outline of tests and trials: 
First Laboratory Visit -Exercise Laboratory, Physiology Department, Nelson 
Mandela Medical School: approx two weeks before trial) 
Interview regarding exercise training status, medical status 
- Assessment of height, mass and percentage body fat (to be estimated fron 
skinfold thicknesses) 
- Lung function test 
- Resting heart rate and blood pressure measurement 
VO; peak test on treadmill: After a 5 minute warm-up at a relevant pace. 
expired air will be collected and analysed as running speed will increase by 
Field visit - University of KZN - Sports grounds Francois Rd Track (approx 
week before trial) 
- Warm up at relevant pace - subject will be timed over 4 laps (1609m) on track 
with heart rate and time recorded. 
Recording and analysis of past and current training processes 
- Analysis of running style and feedback (as above) 
- Race schedule analysis for past month and following month (as above) 
- Explanation of pre- intervention training and eating procedures. 
Intervention Trial to be conducted in the Exercise Laboratory, Nelson R. 
Mandela School of Medicine. 
The protocol of each of the intervention trial will be the following: 
5 davs prior to the trial - 1 x TRAUMEEL tablets 3 X per day (provided) 
sublingually before meals. 
The morning of the trial - the following breakfast is to be eaten 3 hrs before the tria 
:30g cornflakes, 150ml of low fat milk and 12-15 g refined sugar 
The exercise trial - 30ml blood sample to be taken on arrival 
- exercise protocol - wearing a heart rate monitor, six subjects to run or 
treadmill in the exercise laboratory for 90 minutes in a relaxed atmosphere. 
TV screens/music will be available to entertain the runners on the treadmil 
and free communication between runners and research assistants will be 
encouraged. The running speed will be individualized according to the results 
of the V02 max tests and the 1609m time trial. 
- 30ml blood sample will be drawn 1, 24,48 and 72 hours after the trial. 
The order of the trials is to be randomized. By this we mean that you will be placed into 
treatment sequences using random number tables. You may therefore not be receiving the 
treatment in the same order as the other subject(s). As it is to be a double blind study. 
neither the researchers or you will be informed regarding which treatment you are on. 
The products are to be coded as placebo or active substance in the chemical laborator> 
before distribution to the subjects. 
How can you benefit from participation in this study? 
Following completion of all aspects of the trial, you will receive 
the results of your V02rK»k test 
the results of your full blood counts and other biochemical/ laboratory tests which 
were run on your blood samples. 
a prediction of your current ability / potential at various race distances from 5km to 
Comrades marathon (as relevant to your goals / Training) 
a list of training paces relevant to your current ability 
information on your running style and relevance of your current running shoes to thi; 
style. 
an indication, based on the information supplied, as to the relevance of your current 
training to running goals 
A furthering of the knowledge regarding supplementation procedures which will optimize 
x>th your performance and the stiffness you feel following exercise, will be obtained 
from this work. You will be the first to be notified of the results of this study. 
Will you be exposed to adverse effects of the exercise or side effects from Traumeel 
As with all exercise exposure, it is possible that an accident may occur (e.g. that you may 
perhaps fall). In the event of your heart or one of your other organs having a disorder 
which has to date, not been diagnosed, the increased blood flow to the heart and 
increased mean blood pressure during exercise may also result in a heart problem or other 
organ damage occurring while you are exercising. This is the reason why we have beer 
so careful in terms of who we have allowed to participate in the study. Do, however, also 
t>e assured that there will be medical personnel present or on call throughout all aspects 
of the testing and that the laboratory is fulty equipped with first aid and emergenc> 
equipment. 
In terms of possible side-effects from the Traumeel supplementation that you will be 
using, although some people do sometimes develop mild headaches, diarrhoea or nausea, 
recent studies have shown that these resolve without discontinuation of the treatment anc 
it has not been proven that these are directly related to ingestion of Traumeel. 
As with all prolonged exercise involving downhill running, you should expect a certain 
amount of muscle soreness 48-72 hours post-exercise. This will be carefully monitored 
using a 0-10 numerical scale recording your levels of discomfort. It is also worth noting 
that previous studies and coaches suggest that the downhill training session will 
assist In protecting you from muscle soreness and muscle inflammation during other 
downh i l l Sessions Over t h e fol lowing 3 m o n t h s (Nosaka K, Sakamoto K, Newton M, Sacco P. How long 
toes the protective 
effect on eccentric exercise-induced muscle damage last? Med.Sci.Sports Exere., 33: 1490-1495. ). S h o u l d y o u be 
participating in a competitive event involving downhill running following 
participation In this trial, you are therefore assured of a beneficial training effect foi 
at least 3 months thereafter. 
Can you withdraw from the study? 
As participation is entirely voluntary, you may withdraw from the study at any i 
without penalty. 
Will your individual results remain confidential? 
Yes. The records identifying the participant will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly available. 
If the results of the study arc published, the participant's identity will remain confidential 
Sponsorship of the study/Financial compensation 
The Traumeel and placebo products to be used during the study will be manufactured ir 
Germany, and packaged and distributed to you by Heel Pty Ltd, South Africa ir 
Johannesburg. 
Further queries? 
Should you have any queries or wish to obtain further details regarding this study, please 
to not hesitate to contact us. 
Professor Edith Peters-Futre - (031) 260-4237(w); 261-3869(h). 
Study Director 
Department of Physiology, 
Faculty of Health Sciences 
University of KwaZuru-Natal 
Athletics Coach and Consultant: Nome Williamson - 031-2017687 
www. coachnorrie. co. za 
Post-graduate research assistants: 
Dr Aadil Docrat. Department of Physiology 
Ms Megan Smith, Department of Physiology 
Ms Smith and Dr Docrat will be assisting with the implementation of this study and 
writing up sections of the results as part of their M (Med) Sc Degree by coursework 
requirements. 
APPENDIX B 
1, hereby agree to participate in a research study 
to be performed by Edith Peters-Futre and co-workers in the Department of Physiology at 
the University of KwaZulu-Natal Medical School. 
1 understand that the basic procedures involved in this study are to include: 
- Assessments of training history, anthropometric measures, lung function, 
selected baseline clinical measures and an exercise test (VO; peak) during 1" 
Laboratory visit (approx 2 weeks before 90-minute trial in the laboratory). 
Field test conducted by Norrie Williamson which will consist of a 4 lap 
(1609m) time-trial on the KZN athletics track with heart rate and time 
recorded (I week before 90-minute trial in the laboratory). 
Sublingual intake of 1 x TRAUMEEL or placebo tablet 3 x per day 30 
minutes before meals at each meal (i.e. 3 x per day), for 5 days prior to the 
exercise trial (to be held in the Exercise Laboratory, Nelson R Mandela 
School of Medicine. 
- Having a 30ml blood sample taken on arrival at the 90-minute exercise trial. 
Laboratory Exercise Trial: 90minutes of treadmill at an intensity of 75% VO; 
max. Ad libitum ingestion of water will be permitted 30 and 60 minutes into 
the run. 
- Having a 30ml blood sample drawn 1, 24, 48 and 72 hours after both trials. 
- Completing a numerical rating of muscle soreness experienced during the 72 
hours after both exercise trials. 
The details of these procedures have been explained to me in full. I am aware that a 
certain level of discomfort may occur when the blood is taken and that the exercise trials 
will involve strenuous prolonged exercise which may be accompanied by certain medical 
risks and result in muscle soreness in the 48-72 hours post test. I also understand that I do 
not have recourse against the University in the case of an acute medical event occurring 
while I am running on the treadmill. 
I understand that participation is entirely voluntary and that I may withdraw from the 
study at any time. 
Signed 
Date 
Principal Investigators signature 
UNIVERSITY OF 
KWAZULU-NATAL 
Verification from General Practitioner 
is being considered as a potential 
subject in the following research project which is to take place on trained 
endurance athletes in our Department in May 2005. 
Title of Project: The effect of an anti-inflammatory homeopathic product on 
systemic markers of inflammation following downhill running. ____ 
As a precaution we would like you to verify that you have examined this patient 
recently and are not aware that he has any cardiovascular or metabolic problems 
e.g. diabetes which may result in it being hazardous for him to participate in the 
study. 
With sincerest appreciat ion, 
Dr E M Peters-Futre 
Exorcise Physiologist 
Department of Physiology 
Nelson Mandela School of Medicine 
University of KwaZulu Natal 
Private Bag 7, Congella 
4013, South Africa 
Tel; *27(0)31-2604237 
Fax: +27(0)31-2604455 
I hereby confirm that Mr has been 
examined by me and I regard him to be free of cardiovascular impairments which 
may render participation in a 1.5 hr treadmill run hazardous to his health. 
I also confirm that Mr 
is medically fit to participate in this research. 
Signed _ 
is not a diabetic and 
Qualif ication _ 
Date 
Day, Date and Time of 
Session 
Rate of perceived 
exertion 
Training Mileage Intensity Sessions 
Type: 
Duration: 
% of max (eg. 50%): 
Type: 
Duration: 
% of max (eg. 50%): 
rype: 
Duration: 
% of max (eg. 50%): 
Type: 
Duration: 
% of max (eg. 50%): 
Rating of Perceived Exertion 
and General Comments 
1= Very easy 2= Easy 3= Moderate 
4= Fairly Exhausting 5=Exhausted 
APPENDIX C 
UNIVERSITY OF KWA-ZULU NATAL 
DEPARTMENT OF PHYSIOLOGY 
NELSON MANDELA MEDICAL SCHOOL 
Ttee effect «f f raaMti sapjB&anatatiofl fttt Inftnaimtwy 
protowg>d enrobe. 
ATHLETE'S QUESTIONNAIRE 










Average weekly running distance: 
Running History 
Serious\Social: 
Describe normal terrain used for training (to be discussed / confirmed by athletics 
coach) 
Age started running: 
Level of training during these years.. 
Total number of marathons run: 
_( ....yrs) 
[Take into consideration - number of days on flat - number on hills, distance on 
dills, group training, etc) 
Other sports played in last 12 months (squash, rugby weights, etc) 
List peak event(s) for each year of training age (or last 5 years) 
List races / competitions over the last 6 months (all sports) 
List races planned for next 2 months all sports 
Any training group partner in study? If so who? 
Describe your running shoes (make model and age / distance covered) 
Describe your running foot strike (heel-toe / Forefoot / pronation) 
Do you use orthotics? 
Describe the wear pattern on your shoes? 
Personal Best times In last 12 months: 
5 km time trial 8km time trial 
15 km 21.1km 32km . 
42.2km 56 km Comrades ... 
1609m time trial time (will be tested as part of study) ... 
Pace to be used for test (will be filled in after test) 
Please sign: Date: 
Principal investigator's signature: 
MEASUREMENTS 
Pregnancy Test( if female only),. 
Lung Function Tests 
FVC: 
FVC/FEV,: 
Height (cm): Mass (kg): 























VO 2 HR RPE 
tunning Speed at 75% V02 peak": 
APPENDIX D 
Trial Record 
Trial No: _ 
Name: 
Breakfast: 
Resting HR: _ 
Ambient Temperature: 
Dry Bulb: _ 
Pre-Trial Mass: 
Wet Bulb: 
















Study Title: The effects of an anti-inflammatory homeopathic prodact 
on systemic markers of exercise-induced inflammation 
Name Date of Trial: 











Day 4: ; 
after 




Hatotags OH Quads Hanftinps Calf 
0 = no pain at all 
5 = moderate 
10 =severe/maximal 
APPENDIX E 
Do you use Traumeel? 
Wanting to know more 
about it? 
At UKZN we are 
conducting a study on 
the effect of Traumeel on 
exercise-induced 
muscle damage and 
inflammation ... 
What will it involve? 
•One mile field test on UKZN 
athletics track 
•V02 max test 
•One 90-minute downhill run 
following ingestion of 
Traumeel/placebo 
Edith Futre @ 073759797 
Smith @ 0824887557 
for further details 
What will you get out of it? 
•Professional training advice 
from Norrie Williamson 
•Free V02 max test 
•Free blood test results 
•Study results 
If interested, please contact 
or 2604237(w) or Megan 
